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Tuberculosis (TB) is a disease of global concern. Mycobacterium 
tuberculosis (Mtb), the causative agent of TB, has evolved to survive in 
its human host, and it frequently develops resistance to current 
antibiotics targeted against it with the emergence of multi drug-
resistant and extensively drug-resistant strains on the rise. 
Furthermore, current therapeutic interventions for treatment of TB are 
limited in efficacy due to lengthy duration of therapy and severe lung 
damage. Hence, efforts are required to improve TB treatment. Host-
directed therapy (HDT) might be used as an adjunctive treatment for 
TB along with anti-mycobacterials. Here, we characterize small 
molecules as potential candidates for HDT that boost immune 
response by enhancing macrophage activation in the presence of 
interferon gamma (IFNγ) in vitro and in vivo. For the purpose of our 
study, we define macrophage activation as an increase in production 
of pro-inflammatory mediators such as tumor necrosis factor alpha 
(TNFa) and reactive nitrogen intermediates (RNI) and a decrease in the 
production of the anti-inflammatory cytokine – Interleukin 10 (IL-10). 
We also report that protein kinase R (PKR) does not mediate the IFNγ–
dependent production of IL-10 and does not restrain the IFNγ–
dependent production of RNI and TNFa. PKR is dispensable for host 
 control of TB in mice. We show that a small molecule C2062 that 
enhances macrophage activation in vitro, also does so in a mouse 
model of Mtb infection. The phenotype of increased TNFa and RNI 
directly correlates with reduction in bacterial burden, suggesting that 
enhancement of macrophage activation can lead to improved control of 
TB. In addition, C2062 did not exacerbate immunopathology in the 
lung. We further show in Mtb-infected macrophages and a mouse 
model of Mtb infection, that C2062 modestly augments the impact of 
rifampicin, an antibiotic active against Mtb. Thus, targeting the 
pathways leading to enhancement of macrophage activation can be 
used to identify new HDTs that can help the immune system control 
TB in conjunction with anti-mycobacterial drugs. 
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CHAPTER 1 
INTRODUCTION  
 
Tuberculosis - Pathogen, disease, epidemiology and treatment:  
 Tuberculosis (TB) is an ancient infectious disease of humans 
caused by the bacterium Mycobacterium tuberculosis (Mtb). Mtb was 
proven to be the definitive causative agent of tuberculosis by Robert 
Koch in 1882 (Koch 1882). The only natural host of Mtb is H. sapiens 
humans and approximately one-third of the world’s population is 
known to be latently infected with the bacterium (Nathan, 2009). Mtb 
is one of the most successful pathogens in terms of the proportion of 
the population infected (about one-third), the duration of infection 
(usually lifelong), and the number of resulting deaths (2–3 million a 
year, among the most for any single infectious agent) (Nathan and 
Shiloh, 2000). 
 In 2015, there were an estimated 1.4 million deaths from TB 
(Figure 1), and an additional 0.4 million deaths among people living 
with HIV (PLHIV) resulted from TB (WHO, 2016). TB is the most 
prevalent disease amongst PLHIV and the most common illness in 
newly HIV-diagnosed patients (Tiberi et al., 2017). Even though global 
TB incidence has declined slightly in the last decade, TB remained one 
of the top 10 causes of death worldwide in 2015 (WHO, 2016).  
 The advances in TB control are threatened by emergence of Mtb 
strains that are resistant to anti-tuberculosis drugs. The WHO has 
defined multi-drug resistant (MDR) strains as resistant to the two 
frontline drugs isoniazid and rifampicin. Extensively drug-resistant 
 
 
 
3 
(XDR) strains are MDR strains that are also resistant to the 
fluoroquinolones and second-line injectable drugs, suggesting the 
failure of standardized second line treatment regimens. Patients can 
contract drug-resistant TB by two ways: primary resistance by 
infection with a drug-resistant strain and secondary resistance that 
can arise during therapy and is also referred to as acquired resistance 
(Dheda et al., 2017). 
 TB is primarily a disease of the lung and is commonly 
characterized by coughing and weight loss. Mainly, new infections 
occur by inhalation of a droplet containing Mtb expelled from an 
individual suffering from active TB. After exposure, the infection can 
be cleared by one’s immune system; progress to active infection; or be 
contained as a latent disease which is asymptomatic, noncontagious 
and characterized by slowly or non-replicating Mtb (Flynn et al., 2011; 
Russell, 2001). Prevalence and incidence of TB usually varies with 
geographic location. Highest TB burden usually correlates with 
compromised socio-economic status (Dye and Williams, 2010).  
 In the early days, once the etiology of the disease was known 
and primary mode of transmission identified, simple interventions 
such as isolation of patients and improvement of ventilation in 
buildings were used. In 1921, the only licensed vaccine for the 
prevention of TB was developed by the French scientists Albert 
Calmette and Camille Guérin and was accordingly named bacille 
Calmette–Guérin (BCG). Presently, it is the most widely used vaccine 
in the world. It is extensively used to prevent severe forms of extra 
pulmonary TB in infants, but it fails to prevent pulmonary TB (the 
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most common form of the disease)- at any age (Colditz et al., 1994, 
1995). Because of the limitations of BCG, novel vaccine candidates 
have been developed and reached clinical trial pipelines (Kaufmann et 
al., 2017).   
 
 
 
 
 
 
 
 
 
 
 
Fig.1 Percentage of present and relapse pulmonary TB cases with 
bacteriological confirmation in 2014-2015 (Adapted from WHO) 
 
 It is evident that the current strategy to control TB is failing 
and the WHO post-2015 goal of a 90% reduction in the incidence of 
TB by 2035 will not be met without the introduction of new and 
efficacious therapeutic strategies for TB.  
 
Challenges of TB treatment and the need for an alternative 
approach: 
 Despite the availability of antibiotics, TB is a leading cause of 
morbidity and mortality. Improving treatment for drug sensitive and 
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drug-resistant (MDR, XDR) TB is a high priority in the present 
scenario. There are very few antimicrobials targeting Mtb currently 
in clinical trials and some have safety concerns. In addition, Mtb is 
most likely to develop resistance against the new antimicrobials that 
are discovered. In Mtb, drug resistance is associated entirely with 
chromosomal rearrangements and point mutations. Non-adherence 
by patients to the long-term therapy or poor availability of therapy is 
often regarded as a major explanation of drug resistance (Koch and 
Wilkinson, 2014) . 
 The current duration of TB therapy is 6 months in patients 
with drug-sensitive TB and 18-24 months in patients with 
MDR/XDR TB. The patients are also often left with serious 
permanent lung injury following the TB treatment after infection 
despite the infection being cured. 
 The widespread emergence of antimicrobial drug resistant 
strains enhances the need for novel interventions in addition to new 
antimicrobial discovery that could: 
ü   Reduce the length of TB therapy thereby improving patient 
adherence and ameliorating long-term toxicity. 
ü   Augment immune responses to eliminate or contain Mtb. 
ü   Reduce excessive inflammation and / or repair the pulmonary 
damage caused by the infection and functional disability. 
ü   Reduce morbidity and mortality caused by MDR/XDR TB. 
ü   Prevent antimicrobial resistance. 
(Wallis and Hafner, 2015; Zumla et al., 2016) 
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Host directed therapy 
 In the past few years, scientific research has been directed 
towards targeting host biological pathways – rather than pathogen 
components directly -  leading towards development of a range of 
host-directed therapies (HDTs) to achieve an improved clinical 
outcome. An HDT is any substance that can enhance host defense 
mechanisms or regulate excessive inflammation, or both (Wallis and 
Hafner, 2015). HDT should improve clinical treatment outcomes as 
demonstrated by reduced morbidity, mortality, immunopathology and 
long-term recovery. Several HDT agents are currently used (Figure 2). 
An ideal agent for HDT can 
ü   Augment host cellular responses to pathogens without 
exacerbating immunopathology 
ü   Target virulence factors that cause disease 
ü   Activate innate and adaptive immune responses and 
immunological memory. 
 
 
 
  
 
 
 
 
 
 
 
Fig. 2 Main types of host-directed therapies currently in use  
Host directed therapy for TB: 
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 A lot of research has been conducted in the last few years on 
HDT for TB. Some of the key drugs that are currently in clinical trials 
have been summarized in Table 1. 
 
Table 1. Pipeline of host-directed therapies as adjunctive 
treatment of drug-sensitive and drug-resistant TB by modulating 
host pathways. Adapted from (Zumla et al., 2016) 
 
Drug Mechanism of action Stage of 
development 
Fatty acid oxidation and mitochondrial respiration 
Metformin  
(Biguanide) 
Induces ROS production and 
interrupts the mitochondrial chain: 
increases mitochondrial biogenesis 
and respiration 
Preclinical 
Niraparib 
(PARP inhibitor) 
Inhibits PARP-1 and PARP-2 activity; 
impairs repair of DNA single strand 
breaks 
Preclinical 
IL-15  
(Cytokine) 
Maintains and likely induces 
proliferation of CD8 T cells  
Preclinical 
Arachidonic acid metabolism 
Aspirin  
(NSAID) 
Reduces TNFa levels by increasing 
lipoxinA4 production and achieves 
eicosanoid balance during chronic 
inflammation 
Preclinical 
Zileuton 
(Leukotriene 
synthesis inhibitor) 
Activates cyclooxygenase to promote 
prostaglandin production; disrupts 
lipoxygenase activity and blocks 
leukotriene production 
Preclinical 
Ibuprofen 
(NSAID) 
Inhibits cyclooxygenase activity and 
blocks prostaglandin production 
Early phase 
Clinical 
Corticosteroid metabolism 
Prednisone  
(Glucocorticoid 
receptor antagonist) 
Interacts with glucocorticosteroid 
receptor and triggers transcription of 
several host genes critical for Mtb 
elimination i.e. iNOS and 
cyclooxygenase-2 
Mid-late phase 
clinical 
Host cell cytotoxicity 
Cyclophosphamide 
(alkylating agent) 
Cytochrome P450 metabolism of this 
drug produces a complex that can 
alkylate DNA guanine to reduce cell 
proliferation 
Untested in TB 
Etoposide 
(Topoisomerase 
inhibitor) 
Blocks DNA Topoisomerase II to 
prevent re-ligation of nascent DNA 
strands 
Preclinical 
Histone acetylation 
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Table 1 (Contd.) 
Valproic acid and  
vorinostat 
(HDAC inhibitor) 
Acetylates lysine residues on histones 
to promote DNA unwinding and gene 
transcription 
Preclinical 
   
Phenylbutarate 
(HDAC inhibitor) 
Same as above Early phase 
clinical 
Inhibition of tyrosine kinases 
Imatinib mesylate Induces death of cancerous B cells by 
apoptosis; induces myelopoeisis 
Early phase 
Clinical 
Ion efflux channels 
Verapamil 
(Calcium channel 
blocker) 
Modulates voltage gated calcium 
channel activity for maintaining 
cellular homeostasis 
Preclinical 
Carbamazepine 
(sodium channel 
blocker) 
Activates AMPK to induce autophagy; 
activates GABA receptors for 
reducing sensitivity to neuropathic 
pain 
Preclinical 
Statins 
(Inhibitors of 3-
hydroxy-3-
methylglutaryl 
coenzyme reductase 
Blocks endogenous cholesterol 
biosynthesis 
Preclinical 
Immune activation 
GM-CSF. IL-2, 
IFNg (Cytokine) 
Acts towards proliferation and 
activation of macrophages, DCs, 
monocytes and T cells 
Mid-late phase 
clinical 
Innate immune defenses 
Vitamin D3 (Vitamin) Improves antigen presentation, 
induces cathelicidin production and 
augments response to IFNg signaling 
Late phase 
clinical 
Cytokine neutralization 
Adalimumab (anti-
TNFa) (Monoclonal 
antibody) 
Removes excess of TNFa from tissue 
and circulation 
Clinical 
(compassionate 
use) 
Siltuximab (anti- IL-6) 
(Monoclonal antibody) 
Removes excess of IL-6 from tissue 
and circulation 
Preclinical 
Immune checkpoint inhibition 
Ipilimumab (anti-
CTLA4) (Monoclonal 
antibody) 
Blocks CTLA4 to undo T-cell 
exhaustion and restores IL-2 
secretion and signaling 
Preclinical 
Nivolumab (anti-PD-1) 
(Monoclonal antibody) 
Blocks PD-1 to restore lymphocyte 
function. Blocking of PD-L1 on 
surface of APCs aids in T-cell 
activation 
Preclinical 
Anti-Tim3 
(Monoclonal antibody) 
Induces targeted T cell responses by 
regulating Tim3-Gal9 interaction 
Preclinical 
Anti-LAG3 
(Monoclonal antibody) 
Blocks LAG3 to abolish Treg 
interaction with CD4 and CD8 T cell 
Preclinical 
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Table 1 (Contd.) 
 
  
Angiogenesis inhibition 
Bevacizumab (anti-
VEGF) (monoclonal 
antibody) 
Blocks neovascularization induced by 
VEGF in tissues 
Preclinical 
Improved tissue regeneration by reduction of inflammation 
BM-MSCs (Cell-based 
therapy) 
BM-MSCs can reduce severe 
inflammation, regenerate tissues and 
restore positive regulation of immune 
responses, activation of Tregs and 
secretion of soluble factors 
 
 
Host directed therapy for other infectious diseases:  
 Studies of HDT also pave the way for new insights into 
underlying mechanisms of pathogenesis and the hosts’ innate and 
adaptive immune responses. Table 2 lists clinically relevant examples 
in development of candidate HDTs as an adjunctive treatment option 
for viral, parasitic and other bacterial infectious diseases. 
 
Table 2. Pipeline of HDTs as adjunctive treatment for other 
infectious diseases. Adapted from (Zumla et al., 2016) 
 
Drug Mechanism of action Stage of development 
Viral infections   
Human Immunodeficiency Virus 
Anti PD-1 (monoclonal 
antibody) 
Activates antigen-specific 
cells via immune 
checkpoint blockade 
Preclinical 
Hepatitis C virus 
Pegylated IFNa and IFNb 
(cytokine) 
Initiates pro-
inflammatory antiviral 
immune response 
In clinical use 
Adenovirus 
In vitro expanded 
adenovirus-specific CD8 
CTLs. 
(cellular therapy) 
Reduces viral reservoirs 
to avoid uncontrollable 
viremia in individuals 
In clinical use 
Dengue virus 
Dasatinib 
(repurposed drug) 
Tyrosine kinase inhibitor 
inhibits viral replication  
Preclinical 
   
 
 
 
10 
Table 2 (Contd.) 
 
  
Influenza virus   
Atorvastatin (Repurposed 
drug) 
Blocks angiotensin-
converting enzyme that 
reduces pro-inflammatory 
signaling and promotes 
tissue repair 
Mid-late phase clinical 
Parasitic diseases 
Leishmaniasis 
Imiquimod, resiquimod 
(Repurposed drug) 
Induces B-cell activation 
and pro-inflammatory 
signaling as a TLR 
agonist 
In clinical use 
Malaria 
Desferrioxamine 
(Repurposed drug) 
Inhibits ferrochelatase 
and reduces Plasmodium 
sp replication in 
erythrocytes 
Preclinical 
African trypanosomiasis 
IFNg, IL-2, TNFa 
(Cytokine therapy) 
Induces pro-inflammatory 
immune responses and 
intracellular antimicrobial 
activity 
Preclinical 
Schistosomiasis 
Peroxiredoxin (adjuvant 
to vaccine) (recombinant 
protein) 
Modulates hydrogen 
peroxide concentrations 
in host; induces antigen-
specific B-cell responses 
Preclinical 
Bacterial infections   
Streptococcus pneumoniae 
Prednisone (repurposed 
drug) 
Reduces inflammation by 
activating the 
glucocorticoid pathway 
Clinical (current practice) 
Helicobacter pylori   
Vitamin D3 (vitamin) Activates and enhances 
intracellular antimicrobial 
defenses (via IFNg and 
 IL-15 signaling) 
Preclinical 
Bordetella pertussis 
Antipertussis toxin 
antibodies (monoclonal 
antibodies) 
Diminishes the toxin load 
by infusing intravenous 
immunoglobulins 
Preclinical 
 
Overview of host defenses in TB: 
 Once Mtb bacilli are inhaled via aerosol, they reach the alveolar 
space in lungs, where they are taken up by phagocytic cells – primarily 
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lung-resident macrophages. The ability to survive within the 
macrophages is required for Mtb to maintain infection without 
showing any symptoms of disease, a condition termed as latent 
infection. This latency, or ability to persist, allows Mtb to use the 
human host as a reservoir. Mtb requires the ability to proliferate, both 
intracellularly and extracellularly, in order to cause active TB. 
Although TB is mainly a pulmonary disease, Mtb is capable of 
disseminating to most organs and tissues causing several types of TB 
(Lamichhane, 2011) such as miliary TB and extrapulmonary TB 
(spreading to kidney, bone marrow, bone, uterus, lymph nodes, etc.) 
 The early events in Mtb infection are driven by an innate 
immune response initiated by lung-resident macrophages that lead to 
inflammasome activation, cytokine production and initiation of several 
host defense mechanisms such as production of antimicrobial 
peptides, reactive oxygen species (ROS), reactive nitrogen 
intermediates (RNI), natural killer (NK) cells, dendritic cells (DCs), 
epithelial cells and other immune cells add towards this process. 
Neutrophils transfer their granules containing antimicrobial molecules 
that traffic to early endosomes (containing Mtb) – to macrophages and 
the production of S100 proteins. In certain individuals who do not 
develop TB, despite repeated exposure to TB, these innate immune 
responses are likely sufficient to prevent infection.  
 Granulomas are a hallmark of TB infection. A tuberculous 
granuloma is an organized collection of immune cells such as 
macrophages (usually epitheloid), multinucleated giant cells (that are 
formed by macrophage fusion), lymphocytes (both CD4+ and CD8+ T 
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cells, B cells), neutrophils and fibroblasts and is maintained by the 
persistent presence of Mtb (Lin et al., 2007) 
 
Role of IFNg in tuberculosis 
 Interferons (IFNs) can be divided into two major types: Type I 
IFNs are induced in response to viruses: IFNa is secreted by 
leucocytes, and IFNb is produced by fibroblasts. Type II IFNs, known 
as IFNg, is produced by T cells and NK cells upon activation with 
immune and inflammatory stimuli (Cavalcanti et al., 2012). It is the 
most important cytokine involved in the protective immune response 
against mycobacterial infection. It is produced primarily by CD4 and 
CD8 T cells and NK cells. Natural Killer (NKT) cells and γδ T cells can 
also produce IFNg in response to mycobacterial stimulation, 
demonstrating protection against Mtb in vitro and in vivo (Cooper and 
Khader, 2008). The main function of IFNg is to activate macrophages 
and induce their microbicidal functions. It can do so by (a) enhancing 
antigen presentation and promoting differentiation of CD4 T cells into 
Th1 subpopulations (Oberholzer et al., 2000) (b) inducing transcription 
of > 200 genes including those genes that are required for the 
production of antimicrobial molecules like oxygen free radicals and 
nitric oxide, which represent indispensable mechanisms for 
eliminating Mtb (Cooper, 2009).  
 IFNg has been shown to be important in both mice and humans 
in the context of mycobacterial infection. Mice deficient in IFNg are 
highly susceptible to Mtb infection (Cooper et al., 1993; Flynn et al., 
1993). Humans that have a deficiency in the IFNg receptor are 
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extremely susceptible to mycobacterial infections (Newport et al., 
1996). Humans with genetic mutations in the IFNg receptor gene show 
high susceptibility to atypical mycobacterial infections (Jouanguy et 
al., 1996). Patients with less severe forms of pulmonary TB have a 
predominance of IFNg, a Th1 type cytokine, whereas, patients with 
severe forms of TB have an increase in IL-4, a Th2 type cytokine (D et 
al., 1999; Dlugovitzky et al., 1997). Furthermore, patients with active 
TB have a defect in IFNg production in response to a 30kDa antigen 
from Mtb, compared to healthy controls, suggesting that IFNg plays a 
protective role in TB (Torres et al., 1998). 
 
Role of TNFa in tuberculosis 
 TNFa is a pleiotropic cytokine produced mainly by activated 
macrophages, activated T cells, DCs and NK cells (Ehlers, 2003). TNFa 
is important for activation of macrophages and immune cell 
recruitment to the site of infection. It is critical in granuloma formation 
and maintenance.  
 Deficiency of the TNF gene or its receptor in mice results in 
acute TB (Bean et al., 1999; Flynn et al., 1995). Neutralization of TNFa 
has been shown to cause reactivation of TB (Mohan et al., 2001). 
Patients suffering from rheumatoid arthritis who are undergoing 
treatment with TNFa antagonists, are at significantly increased risk of 
reactivating latent Mtb (Solovic et al., 2010). TNFα is also known to 
increase the capacity of macrophages to phagocytose and kill 
mycobacteria; to stimulate apoptosis of macrophages thereby 
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depriving bacilli of host cells and causing death; and presentation by 
dendritic cells of mycobacterial antigens (Cavalcanti et al., 2012) 
 
Role of IL-10 in tuberculosis 
 IL-10 is a cytokine with pleiotropic immunoregulatory roles. It is 
produced by macrophages and T cells during Mtb infection. In contrast 
to IFNg and TNFa, it is mainly an anti-inflammatory cytokine, critical 
for balance between inflammatory and immunopathological responses. 
IL-10-/- mice on C57BL/6 background had reduced BCG burden 
compared to controls suggesting that deficiency in IL-10 promotes 
anti-mycobacterial immunity (Murray and Young, 1999). In Mtb-
susceptible CBA/J mice, treatment with IL-10 blocking antibodies 
during chronic infection, improved survival by stabilizing bacterial 
burden in the lung (Beamer et al., 2008). These findings suggest that 
IL-10 promotes TB disease progression.  
 Detailed studies of IL-10 gene polymorphisms associated with 
infectious diseases suggests that polymorphisms associated with this 
gene have an important role in immunity and progression of 
inflammation. In humans, an SNP associated with IL-10 promoter was 
shown to be associated with decreased risk of TB (Shin et al., 2005). 
The aim of Mtb is to survive in the host by lowering the protective 
cellular immune responses. IL-10, TGF-bRII and other inhibitory 
molecules of inflammatory response were detected in sputum from TB 
patients, and 30 days post treatment, their levels decreased 
considerably with a concomitant increase in Th1 cytokines (Almeida et 
al., 2009). However, a study did not observe increased levels of IL-10 
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in peripheral blood mononuclear cells (PBMCs) from MDR-TB patients 
in response to mycobacterial antigens (McDyer et al., 1997). 
 
Role of RNI in tuberculosis 
 RNI, or reactive nitrogen intermediates, refer to oxidation states 
and adducts of the nitrogenous products of the enzyme - nitric oxide 
synthase, such as nitric oxide (NO), nitrate (NO3), nitrite (NO2), 
peroxynitrite (OONO2), S-nitrosothiols and dinitrosyl iron complexes 
(Nathan and Shiloh, 2000). RNI are produced by several cells and can 
damage DNA and several enzymes that are required for the protection 
and replication of DNA. NO is toxic and a potent effector of 
macrophage bactericidal and bacteriostatic activities (Ding et al., 1988; 
Liew and Cox, 1991). One such enzyme, NOS2 (Nitric Oxide Synthase 
2 or iNOS) is responsible for production of RNI. 
 Mice deficient in the gene Nos2 are highly susceptible to Mtb 
infection (MacMicking et al., 1997). RNI production has been shown to 
be necessary for control of Mtb infection caused by both laboratory 
and clinical strains (Scanga et al., 2001).  Treatment with NOS2 
inhibitors worsen Mtb infection in mice either in chronic or acute 
phase of Mtb infection (Nathan and Shiloh, 2000). Macrophages 
isolated from the lungs of TB patients express Nos2  in amounts that 
are bactericidal to Mtb (Nicholson et al., 1996; Rich et al., 1997; Wang 
et al., 1998). 
 
Role of neutrophils in tuberculosis                                                                       
The overall role of neutrophils during Mtb infection is not fully  
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understood. As mentioned above, animals lacking IFNg or Nos2 suffer 
from severe TB with increased bacterial burden and granulocytic 
inflammation. This correlation between granulocytes such as 
neutrophils and polymorphonuclear cells (PMNs), bacterial load and 
pathology is commonly observed in both animal models and TB 
patients (Berry et al., 2010; Eruslanov et al., 2005; Mattila et al., 
2015). It has been suggested that Mtb infection induces a 
proinflammatory response that leads to the recruitment of PMNs to the 
lung. Loss of Atg5 expression within the responding myeloid cells has 
been shown to cause uncontrolled accumulation of PMNs in the lung, 
in turn causing increased pathology and an expanded niche for 
bacterial replication (Kimmey et al., 2015). Neutrophilic inflammation 
has been shown to generate a nutrient replete niche that promotes 
Mtb growth, suggesting that Mtb exploits neutrophilic inflammation to 
preferentially replicate in areas of tissue damage in order to promote 
the dissemination of infection (Mishra et al., 2017). In I/St mice (that 
are genetically hyper-susceptible to Mtb infection). neutrophils have 
been implicated as a “Trojan horse” for mycobacteria and aid in the 
development of severe lung inflammation instead of protection of the 
host (Eruslanov et al., 2005). This was not observed in A/Sn mice (that 
are known to be resistant to Mtb infection). Furthermore, neutrophil 
depletion in vivo in Mtb-infected I/St mice reduced lung pathology and 
bacterial burden, resulting in an increase in survival time (Yeremeev et 
al., 2015), thereby providing evidence of the deleterious instead of a 
protective role of neutrophils in Mtb infection. 
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 However, neutrophils have been implicated in generation of Th1 
and Th17 cells in response to tuberculosis vaccine. Depletion of 
neutrophils during vaccination abolished the induction the Th1-
specific responses and prevented the reduction of bacterial burden in 
vaccinated animals (Trentini et al., 2016). Hence, neutrophils are 
multifunctional cells that play a dual role in Mtb infection. They can 
be bactericidal, participate in granuloma formation and development 
of adaptive immunity; at the same time, they may support Mtb growth, 
mediate tissue destruction, disease severity and progression. It has 
been suggested that TB disease alters neutrophil population leading to 
accumulation of heterogeneous subsets of activated dysfunctional cells 
and a decline in true neutrophils (Lyadova, 2017). The precise role of 
neutrophils in Mtb infection is yet to be determined. 
 
Conclusions 
 In the context of tuberculosis, host directed therapy would be 
used as an adjunctive treatment for Mtb along with anti-
mycobacterials. We chose to develop a candidate for HDT that boosts 
the immune response by enhancing macrophage activation in mice. 
We screened and identified small molecules that increased the 
production of pro-inflammatory mediators described earlier – TNFa 
and RNI, and reduced the production of IL-10 (Discussed in Chapter 
2). We tested the lead inhibitors in the context of Mtb infection in mice 
and initiated steps to identify the mechanism of action (Discussed in 
Chapter 3). Please see Figure 3 for a schematic respresentation of our 
working model. 
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Fig. 3 Model 
A.   We target macrophages with small molecules in order to 
enhance their activation as measured by an increase in 
production of TNFa and nitrite and decrease in IL-10. 
B.   Our goal is to clear Mtb by using small molecules to enhance 
macrophage activation, in addition to existing anti-
mycobacterials without exacerbating immunopathology. 
NO2!
Nitrite
TNFα IL!10
IFNγ
M.#tuberculosis
Super!activated(macrophage
M.#tuberculosis
ENEMY!
Super!activated(macrophage Anti!mycobacterials
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CHAPTER TWO 
PROTEIN KINASE R IS DISPENSABLE FOR HOST CONTROL OF 
TUBERCULOSIS IN MICE1 
 
SUMMARY 
Genetic deletion of protein kinase R (PKR) in mice was reported (Wu et 
al., 2012) to enhance macrophage activation in vitro in response to 
interferon-g (IFNg) and to reduce the burden of Mycobacterium 
tuberculosis (Mtb) in vivo. Consistent with this, treatment of wild-type 
(WT) macrophages in vitro with a novel PKR inhibitor (Bryk et al., 
2011) also enhanced IFNγ–dependent macrophage activation. Herein, 
co-treatment with IFNg and a highly selective PKR inhibitor likewise 
induced macrophages to produce more reactive nitrogen intermediates 
(RNI) and tumor necrosis factor alpha (TNFα) and less interleukin 10 
(IL-10) than IFNg alone. Surprisingly, the PKR inhibitor had a 
comparable effect on PKR-deficient macrophages. The retrospective 
investigation revealed that PKR-deficient mice used in the original 
study had not been backcrossed. On comparing extensively genetically 
matched PKR-deficient and WT mice, we saw no impact of PKR 
deficiency on macrophage activation in vitro or during the course of 
infection in vivo. Responses of 129S1/SvImJ macrophages to IFNγ 
were much greater than those of C57BL/6 macrophages, but PKR was 
not required to mediate the IFNγ–dependent production of IL-10 and 
did not restrain the IFNγ–dependent production of RNI and TNFa. 
                                                
1 Shashirekha Mundhra, Ruslana Bryk, Natalie Hawryluk, Tuo Zhang,  Xiuju Jiang, 
Carl F. Nathan. Protein kinase R is dispensable for host control of tuberculosis in 
mice. (Manuscript in Submission). 
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INTRODUCTION 
  
            Tuberculosis (TB) is now the leading cause of death by a single 
infectious agent in humans. The World Health Organization (WHO) has 
estimated that 2015 witnessed 10.4 million new TB cases and 1.8 
million deaths from TB. The emergence of multidrug-resistant (MDR) 
and extensively drug-resistant (XDR) TB in individuals in more than 
100 countries increases the global threat. The effort to find new 
treatments has expanded to consider potential host-directed therapies 
(HDT) (Wallis and Hafner, 2015)(Zumla et al., 2016).  
 One target proposed as a candidate for HDT was protein kinase 
R (Wu et al., 2012). PKR is a widely expressed serine/threonine protein 
kinase (Fig. 1) that is activated by double-stranded RNA (dsRNA) 
(Proud, 1995; Robertson and Mathews, 1996; Williams, 1999). Binding 
of dsRNA promotes PKR’s homodimerization, autophosphorylation, 
and activation (Dey et al., 2005). PKR function is diverse and well-
characterized.  PKR is induced by type I IFN, and reciprocally, 
enhances IFN-α/β production by stabilizing IFN-α/β mRNA in 
response to several RNA viruses, such as Semiliki Forest Virus (Schulz 
et al., 2010). PKR promotes antiviral activity by inhibiting translation 
through phosphorylation of eukaryotic initiation factor 2a (eIF-2α) (de 
Haro et al., 1996). PKR can be activated in response to 
lipopolysaccharide (LPS), cytokines such as IFNg, IL-1 and TNFa, 
oxidative stress and polyanions such as heparin and dextran sulphate 
(Williams, 2001) and it can mediate an inflammatory response through 
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activation of NF-kB (Zamanian-Daryoush et al., 2000). PKR also has 
pro-apoptotic functions (Der et al., 1997). 
 Despite PKR’s widespread actions, its genetic disruption does 
not produce an overt phenotype in mice unless they are infected with 
certain pathogens. In fact, during Mtb infection, PKR-deficient mice 
had a reduced mycobacterial burden and less immunopathology than 
PKR-sufficient mice (Wu et al., 2012). In vivo and in vitro, PKR-
deficient macrophages underwent more apoptosis than WT 
macrophages when infected with Mtb (Wu et al., 2012). In response to 
IFNγ, PKR-deficient macrophages produced more inducible nitric oxide 
synthase (iNOS), RNI and TNFa than PKR-sufficient macrophages (Wu 
et al., 2012). The inference that the difference in expression of PKR 
was a critical factor in those experiments was reinforced by evidence 
that treatment of WT macrophages with a PKR inhibitor, N-(2(1H-
indol-3-yl)ethyl)-4-(2-methyl-1H-indol-3-yl)-pyrimin-2-amine increased 
the extent of macrophage activation in response to IFNg above that 
seen with IFNg alone (Bryk et al., 2011). Treatment of macrophages 
with IFNγ induced the production of IL-10 (Wu et al., 2012), a cytokine 
that opposes many of the actions of IFNγ on macrophages (Bogdan et 
al., 1991). The IFNγ-dependent induction of IL-10 was markedly 
reduced in PKR-deficient macrophages, and reduction in IL-10 
contributed to the ability of PKR-deficient macrophages to respond 
more robustly to IFNγ than WT macrophages (Wu et al., 2012). For all 
these reasons, inhibition of PKR appeared to hold promise as a 
candidate for HDT of TB. 
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  The PKR inhibitor, N-(2(1H-indol-3-yl)ethyl)-4-(2-methyl-1H-
indol-3-yl)-pyrimin-2-amine developed earlier (Bryk et al., 2011) was 
not characterized in terms of its selectivity. We set out to develop a 
highly selective PKR inhibitor. As part of our analysis of potential 
inhibitors, we compared their impact on macrophages that did or did 
not contain PKR. To our surprise, their effect was similar whether 
macrophages contained PKR or not. This prompted a re-investigation 
of the earlier study on responses of PKR-deficient macrophages to Mtb 
(Wu et al., 2012). An issue was uncovered regarding the backcrossing 
of those mice, so we repeated key observations of that work using 
macrophages from two strains of PKR knockout mice- those deficient 
either in the regulatory domain or in the kinase domain of PKR (Yang 
et al., 1995) (Abraham et al., 1999)- whose genetic background we 
confirmed. We also studied the course of Mtb infection in co-housed 
mice of the F2 generation arising from a PKR KO and background-
matched WT parental strains. The results revealed that macrophages 
from 129S1/SvImJ mice respond much more robustly to IFNγ than 
those from C57BL/6J mice, but PKR plays no appreciable role in the 
response of mouse macrophages to IFNγ in vitro or in the course of 
Mtb infection in vivo. Hence, PKR can be ruled out as a target for HDT. 
 
 
 
 
 
Fig. 1 Schematic representation of domains of protein kinase R. 
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RESULTS  
Screening of kinase inhibitors for macrophage activation 
phenotypes in collaboration with Celgene Global Health. 
 Since PKR was reported to be important in the control of TB (Wu 
et al., 2012), we hypothesized that targeting PKR would be an effective 
strategy for HDT of TB. A PKR inhibitor used extensively in the 
literature, Imoxin (C16) (Nakamura et al., 2014) was found to inhibit 
107 out of 258 kinases when tested at a concentration of 3 µM (Table 
1), confirming its non-specificity. The PKR inhibitor developed earlier, 
N-[2-(1H-indol-3-yl)ethyl]-4-(2-methyl-1H-indol-3-yl)pyrimidin-2-amine 
(compound 51) (Bryk et al., 2011) was not characterized in terms of its 
selectivity. This necessitated a search for a selective PKR inhibitor to 
be used as HDT for TB. We collaborated with Celgene Global Health 
(CGH) to develop PKR inhibitors with better characterized selectivity 
than those reported to date. My colleague, Ruslana Bryk screened a 
small molecule kinase library from CGH against recombinant human 
PKR, and together we screened on bone marrow-derived macrophages 
(BMMs) for the three phenotypes – elevation of nitrite and TNFa and 
reduction of IL-10 compared to controls, in the presence of IFNg. Fig. 2 
describes a flowchart of the screening process along with the 
experimental design. Table 2 lists all the compounds that were tested 
for this thesis. 
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Table 1. Kinase selectivity panel of Imoxin  
Imoxin was tested at 3 µM for kinase selectivity assay performed at 
Life Technologies' SelectScreen® Profiling Service) for Celgene Global 
Health. The values are mean of % activity remaining, calculated by 
subtracting the mean of % inhibition from 100 %. The kinases for 
which mean % inhibition was > 80 (% activity remaining < 20) have 
been highlighted in red. 
 
 
 
 
Kinase Imoxin'@''3.0'μM Kinase Imoxin'@''3.0'μM Kinase Imoxin'@''3.0'μM Kinase Imoxin'@''3.0'μM
ABL1 13 EGFR%(ErbB1)%L858R 95 LYN$B 88 PLK2 7
ABL1%E255K 22 EGFR%(ErbB1)%L861Q 89 MAP2K1'(MEK1) 2 PLK3 45
ABL1%G250E 16 EGFR%(ErbB1)%T790M 46 MAP2K2&(MEK2) 113 PRKACA&(PKA) 10
ABL1%T315I 76 EGFR%(ErbB1)%T790M%L858R 35 MAP2K6'(MKK6) 7 PRKCA&(PKC&alpha) 11
ABL1%Y253F 20 EPHA1 35 MAP3K8'(COT) 1 PRKCB1'(PKC'beta'I) 39
ABL2%(mouse) 37 EPHA2 39 MAP3K9'(MLK1) 7 PRKCB2'(PKC'beta'II) 41
ACVR1B'(ALK4) 60 EPHA4 36 MAP4K2'(GCK) 0 PRKCD&(PKC&delta) 7
ADRBK1'(GRK2) 91 EPHA5 99 MAP4K4&(HGK) !5 PRKCE&(PKC&epsilon) 33
ADRBK2'(GRK3) 97 EPHA8 79 MAP4K5'(KHS1) 2 PRKCG&(PKC&gamma) 32
AKT1%(PKB%alpha) 76 EPHB1 19 MAPK1&(ERK2) 2 PRKCH&(PKC&eta) 11
AKT2%(PKB%beta) 72 EPHB2 38 MAPK10'(JNK3) 32 PRKCI&(PKC&iota) 81
AKT3%(PKB%gamma) 69 EPHB3 60 MAPK11&(p38&beta) 93 PRKCN&(PKD3) 39
AMPK%A1/B1/G1 1 EPHB4 96 MAPK12'(p38'gamma) 15 PRKCQ&(PKC&theta) 39
AMPK%A2/B1/G1 3 ERBB2%(HER2) 97 MAPK13'(p38'delta) 27 PRKCZ&(PKC&zeta) 81
AURKA%(Aurora%A) 2 ERBB4%(HER4) 70 MAPK14'(p38'alpha) 85,$99 PRKD1&(PKC&mu) 20
AURKB&(Aurora&B) 9 FER 21 MAPK3&(ERK1) !1 PRKD2&(PKD2) 14
AURKC&(Aurora&C) 25 FES$(FPS) 21 MAPK8&(JNK1) 23 PRKG1 9
AXL 43 FGFR1 11 MAPK9&(JNK2) 13 PRKG2&(PKG2) 5
BLK 20 FGFR2 50 MAPKAPK2 84 PRKX 7
BMX 95 FGFR3 62 MAPKAPK3 80 PTK2%(FAK) 39
BRAF 104 FGFR3%K650E 4 MAPKAPK5&(PRAK) 53 PTK2B&(FAK2) 91
BRAF%V599E !4 FGFR4 91 MARK1&(MARK) 6 PTK6%(Brk) 77
BRSK1&(SAD1) 0 FGR 10 MARK2 5 RAF1%(cRAF)%Y340D%Y341D 1
BTK 91 FLT1%(VEGFR1) 88 MATK%(HYL) 94 RET 3
CAMK1D'(CaMKI'delta) 67 FLT3 !5 MELK 4 RET$V804L 1
CAMK2A&(CaMKII&alpha) 15 FLT3%D835Y 1 MERTK&(cMER) 83 RET$Y791F 1
CAMK2B'(CaMKII'beta) 97 FLT4%(VEGFR3) 8 MET$(cMet) 81 ROCK1 7
CAMK2D'(CaMKII'delta) 6 FRAP1&(mTOR) 97 MET$M1250T 11 ROCK2 9
CAMK4&(CaMKIV) 65 FRK$(PTK5) 109 MINK1 !1 ROS1 95
CDC42%BPA%(MRCKA) 78 FYN 45 MKNK1%(MNK1) 2 RPS6KA1((RSK1) 8
CDC42%BPB%(MRCKB) 78 GRK4 37 MST1R&(RON) 62 RPS6KA2((RSK3) 2
CDK1/cyclin+B 0 GRK5 55 MST4 !1 RPS6KA3((RSK2) 8
CDK2/cyclin+A 2 GRK6 25 MUSK 95 RPS6KA4((MSK2) 1
CDK5/p25 2 GRK7 20 MYLK2&(skMLCK) !1 RPS6KA5((MSK1) 12
CDK5/p35 1 GSG2$(Haspin) 0 NEK1 14 RPS6KA6'(RSK4) 67
CDK7/cyclin+H/MNAT1 6 GSK3A&(GSK3&alpha) 0 NEK2 76 RPS6KB1((p70S6K) 18
CDK9/cyclin+T1 0 GSK3B&(GSK3&beta) 1 NEK4 88 SGK$(SGK1) 5
CHEK1&(CHK1) 3 HCK 41 NEK6 54 SGK2 8
CHEK2&(CHK2) 17 HIPK1&(Myak) 22 NEK7 76 SGKL%(SGK3) 31
CHUK%(IKK%alpha) 0 HIPK2 9 NEK9 25 SNF1LK2 14
CLK1 3 HIPK3&(YAK1) 24 NTRK1&(TRKA) 3 SRC 88
CLK2 1 HIPK4 24 NTRK2&(TRKB) 71 SRC$N1 31
CLK3 29 IGF1R 79 NTRK3&(TRKC) 62 SRMS$(Srm) 98
CSF1R&(FMS) 76 IKBKB$(IKK$beta) 29 NUAK1&(ARK5) 2 SRPK1 88
CSK 70 IKBKE%(IKK%epsilon) 14 PAK1 85 SRPK2 97
CSNK1A1'(CK1'alpha'1) 72 INSR 69 PAK2%(PAK65) 68 STK22B&(TSSK2) 91
CSNK1D'(CK1'delta) 21 INSRR%(IRR) 88 PAK3 79 STK22D&(TSSK1) 37
CSNK1E'(CK1'epsilon) 14 IRAK1 5 PAK4 45 STK23&(MSSK1) 96
CSNK1G1'(CK1'gamma'1) 68 IRAK4 21 PAK6 75 STK24&(MST3) !5
CSNK1G2((CK1(gamma(2) 62 ITK 96 PAK7%(KIAA1264) 91 STK25&(YSK1) 2
CSNK1G3((CK1(gamma(3) 65 JAK1 90 PASK 23 STK3%(MST2) !2
CSNK2A1((CK2(alpha(1) 64 JAK2 15 PDGFRA'(PDGFR'alpha) 52 STK4%(MST1) 1
CSNK2A2'(CK2'alpha'2) 33 JAK2%JH1%JH2 26 PDGFRA'D842V 5 SYK 77
DAPK1 18 JAK2%JH1%JH2%V617F 24 PDGFRA'T674I 11 TAOK2&(TAO1) 33
DAPK3&(ZIPK) 24 JAK3 70 PDGFRA'V561D 7 TBK1 89
DCAMKL2((DCK2) 90 KDR$(VEGFR2) 1 PDGFRB'(PDGFR'beta) 25 TEK$(Tie2) 33
DNA$PK 23 KIT 101 PDK1 12,$4 TTK !2
DYRK1A 5 KIT$T670I 26 PHKG1 14 TXK 80
DYRK1B 4 LCK 19 PHKG2 18 TYK2 3
DYRK3 6 LRRK2 0 PIM1 19 TYRO3&(RSE) 91
DYRK4 49 LRRK2%G2019S 0 PIM2 28 YES1 90
EEF2K 90 LTK$(TYK1) 55 PKN1%(PRK1) 27 ZAP70 104
EGFR%(ErbB1) 83 LYN$A 22 PLK1 72 Hit_Score20 107$of$258
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Fig. 2. Flowchart describing the progression of screening of PKR 
inhibitors. 
 R. Bryk performed all assays against human recombinant PKR. S. 
Mundhra screened compounds on BMMs along with R. Bryk. S.Mundhra 
performed all ELISAs and graphed the data. A cluster refers to a class 
of chemical compounds with structural and physicochemical 
similarities. 
 
 
 
 
 
 
Three%rounds%of%screening%against%recombinant%human%PKR%to%identify%
potential)clusters)– 1625%compounds% %representing%11%structural%series
4"potential"clusters"were"identified"–
86#compounds#had#IC50#ranging&from&0.1&μM"– 1"μM
155#compounds;#Clusters#2,3#and#10#were#tested#on#bone#marrow!derived&
macrophages+treated+with+ /! IFNγ (24$hours)
Nitrite
(Griess Assay)
TNFα
(ELISA)
IL!10
(ELISA)
Three%rounds%of%screening%against%recombinant%human%PKR%to%identify%
potential)clusters)– 1625%compounds% %representing%11%structural%series
4"potential"clusters"were"identified"–
86#compounds#had#IC50#ranging&from&0.1&μM"– 1"μM
155#compounds;#Clusters#2,3#and#10#were#tested#on#bone#marrow!derived&
macrophages+treated+with+ /! IFNγ (24$hours)
Nitrite
(Griess Assay)
TNFα
(ELISA)
IL!10
(ELISA)
Day$0
Isolate$bone$
marrow$from$
C57BL/6J$mice
Day$6
Differentiation
Plate$cells$
( /? IFNγ)
Day$7 Day$9
Replace$media$
with$compounds$
(+/? IFNγ)
Harvest$$culture$
supernatants
Treatment$with$compounds
Day$8
Observe$cells$
for$toxicity
 
 
 
33 
Table 2. Compounds tested in bone marrow-derived macrophages, 
with their phenotypes in presence of IFNg.  
The compounds highlighted in yellow were tested in a mouse model of 
Mtb infection. (Discussed in Chapter 3).  
TNFa:  +++ >200 pg/ml; ++ 100-200 pg/ml; + 50-100 pg/ml;  
IL10: +++ 75-95% reduction; ++ 50-75%; + <50% reduction;  
Nitrite: +++ > 20 µM; ++ 10-19 µM; + 5-10 µM  
DNT Did not test 
  
No. Nitrite TNFα IL#10 CC# No. Nitrite TNFα IL#10 CC# No. Nitrite TNFα IL#10 CC#
C1 + ! + CC0223160 C51 + ! + CC0387223 2006 ! DNT DNT CC0775206
C2 ! ! ! CC0223522 C52 ! ! + CC0386932 2007 ++ + +++ CC0775207
C3 ! ! ! CC0223643 C53 ! ! + CC0386661 2008 ! + ! CC0775208
C4 ! ! ! CC0224900 C54 ! ! + CC0386662 2009 ! DNT DNT CC0775209
C5 ! ! ! CC0120633 C55 +++ ++ +++ CC0338364 2010 ++ ++ +++ CC0775210
C6 ++ + +++ CC0127685 C56 ++ ++ +++ CC0338378 2011 ++ + ++ CC0775211
C7 ! ! ! CC0313679 C57 ++ + +++ CC0327075 2013 ++ + +++ CC0776037
C8 ++ + ++ CC0337140 C58 ! + ++ CC0225128 2014 ! DNT DNT CC0776038
C9 ! ! ! CC0342376 C59 ! ! ++ CC0477489 2015 ! DNT DNT CC0776039
C10 ! ! ! CC0418422 C60 ! ! + CC0191770 2016 ++ + +++ CC0776040
C11 ! ! ! CC0418340 C61 ! ! ++ CC0185965 2017 ++ + ++ CC0776041
C12 + ! ! CC0741175 C62 ! ! +++ CC0225144 2018 ! DNT DNT CC0776042
C13 ! ! ! CC0209934 C63 ++ + +++ CC0386754 2019 ! DNT DNT CC0776043
C14 ! ! ! CC0223190 C64 ! ! + CC0387222 2020 ! DNT DNT CC0776044
C15 ! ! ! CC0224002 C65 ++ ++ +++ CC0387522 2021 ! DNT DNT CC0776045
C16 ! ! ! CC0224004 C66 ! ! + CC0195706 2022 ! DNT DNT CC0776046
C17
! ! !
CC0223188 C67
! ! +++ CC0327041 2031 ! ! ++ CC0776118
C18 ! ! ! CC0224724 C68 ! ! ++ CC0327111 2032 ! ! ++ CC0776119
C19 ! ! ! CC0224830 C69 ! ! ++ CC0342333 2033 +++ + +++ CC0776120
C20 ! ! ! CC0224837 C70 ! ! +++ CC0386702 2034 +++ ++ +++ CC0776121
C21 ! ! ! CC0224894 C71 +++ + +++ CC0342393 2042 ! ! + CC0776401
C22 ! ! ! CC0225105 C72 ! ! +++ CC0415593 2043 ! ! ! CC0776402
C23 + + +++ CC0225707 C73 ! ! +++ CC0415447 2044 ! ++ +++ CC0776403
C24 ++ ! ++ CC0225137 C74 ! ! +++ CC0418912 2045 ! ! + CC0776404
C25 ! ! + CC0120729 C75 ++ ! ++ CC0338366 2046 ! DNT DNT CC0776876
C26 ! ! ! CC0145783 C76 ! ! ++ CC0199406 2047 ! ! ++ CC0776877
C27 ++ + + CC0387097 C77 ++ ! +++ CC0225146 2048 ! DNT DNT CC0776878
C28 ! + ! CC0387495 C78 ! ++ +++ CC0338382 2049 ! DNT DNT CC0776879
C29 +++ ++ +++ CC0390602 C79 ! ! +++ CC0327104 2050 ! DNT DNT CC0777483
C30 ! ! + CC0185921 C80 ! ! +++ CC0342369 2051 ! ! +++ CC0777484
C31 ! ! ! CC0195708 C81 ! ! ++ CC0342330 2060 ! DNT DNT CC0777877
C32 ! ! + CC0193701 C82 ! ! + CC0338381 2061 ! ! ! CC0777878
C33 ! ! ! CC0195707 C83 ! + +++ CC0338449 2062 +++ ++ +++ CC0777879
C34 ++ + +++ CC0326986 C84 ! + ! CC0387518 2063 ! DNT DNT CC0777880
C35 ++ + +++ CC0338377 C85 +++ ++ +++ CC0387206 2064 ! DNT DNT CC0777881
C36 + + +++ CC0326965 C90 ! ! ! CC0338418 2067 ! DNT DNT CC0778344
C37 ! ! ! CC0342377 C91 ++ + +++ CC0327112 2068 ! ! ++ CC0778345
C38 ++ + ++ CC0386753 C92 ! ! ! CC0387222 2069 ! ! +++ CC0778346
C39 ! ! ! CC0418512 C93 ! ! ! CC0342396 2070 + + ++ CC0778347
C40 ! ! ! CC0440647 C94 ! ! ! CC0225107 2071 ++ + +++ CC0778348
C41 +++ +++ ++ CC0326962 C95 ! ! ! CC0417775 2072 ! DNT DNT CC0778349
C42 ! ! increase CC0387762 C96 ! ! ! CC0480383 2073 ! DNT DNT CC0778350
C43 ! ! +++ CC0477769 C97 ! ! ! CC0224626 2074 ! DNT DNT CC0778351
C44 ++ +++ + CC0223159 1999 ! DNT DNT CC0775199 2081 ! DNT DNT CC0778729
C45 + ++ ++ CC0195742 2000 ! DNT DNT CC0775200 2082 ! ! ++ CC0778730
C46 ! ! ! CC0386751 2001 ! DNT DNT CC0775201 2083 ! DNT DNT CC0778731
C47 ! ! + CC0227142 2002 ++ ! +++ CC0775202 2084 ! ! ++ CC0778732
C48 ! ! CC0225101 2003 + + +++ CC0775203 2833 ! ! !
C49 ! ! CC0224989 2004 ++ ++ +++ CC0775204
C50 ! + + CC0127686 2005 ! DNT DNT CC0775205
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Testing of a relatively selective PKR inhibitor on wild-type 
macrophages 
 A screen of over 2000 kinase inhibitors and their congeners in a 
CGH library against recombinant human PKR was conducted. C85 
was one of 160 compounds identified as active and was tested for its 
ability to increase the release of nitrite and TNFα and to decrease the 
release of IL-10 from BMMs from WT C57BL/6J mice that had been 
treated with IFNγ (10 ng/mL) for 24 hours. C85 was an ATP-
competitive inhibitor with an IC50 of 23 nM against PKR (Fig. 3A). C85 
was relatively selective, in that it inhibited only 5 out of 258 kinases 
when tested at a concentration of 3 µM (Table 3). C85 was not toxic to 
BMMs (Fig. 3B). Treatment of IFNγ-primed, WT C57BL/6J BMMs with 
C85 led to a marked reduction in IL-10 and a marked increase in RNI 
and TNFα compared to exposure to IFNγ alone (Fig. 3C). These results 
appeared consistent with those reported using a chemically distinct 
inhibitor of uncharacterized specificity (Wu et al., 2012). However, the 
kinome includes more than 200 additional enzymes whose possible 
inhibition by C85 was not tested. To establish whether the effect of 
C85 on macrophages was due to inhibition of PKR or other targets, we 
next tested C85 on macrophages from WT and PKR KO mice. 
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Figure 3. Compound 85 inhibits PKR in vitro and enhances 
macrophage activation with minimal toxicity. 
A)   Concentration-response for inhibition of human PKR by C85 at 
10 µM ATP (red circles) or 20 µM ATP (black circles) or 40 µM 
(blue circles). R. Bryk contributed this figure. 
B)   Images of BMMs treated with indicated concentrations of C85 for 
24 hr at 20X magnification. . 
C)   Dose-response curve of C85 and its impact on IL-10 reduction, 
nitrite production and TNFa production on WT BMMs primed 
with IFNg (10 ng/ml) for 24 hr then treated with C85 for 48 hr. 
Results in (C) are means ± SEM of two independent experiments 
each performed in triplicate. p < 0.05 = *; p < 0.01 = **; p < 
0.005 = ***; p < 0.001 = ****.    
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Table 3. Kinase Selectivity of C85 
C85 was at tested at 3 µM for kinase selectivity in an assay 
performed at Life Technologies' SelectScreen® Profiling Service for 
Celgene Global Health. The values are mean % activity remaining, 
calculated by subtracting mean % inhibition from 100 %. The 
kinases where mean % inhibition was > 80 (% activity remaining < 
20) have been highlighted in red. 
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PKR expression in the C57BL/6J background does not impact the 
effect of C85 on macrophage activation. 
 To test whether PKR was the functionally relevant target of C85 
in macrophage activation, we obtained extensively backcrossed 
breeding pairs of a PKR knockout strain deficient in the PKR kinase 
domain (Abraham et al., 1999; Lu et al., 2012) and femurs from 
another PKR knockout strain lacking in the PKR regulatory domain 
(Chakrabarti et al., 2008; Yang et al., 1995). We confirmed that their 
genetic backgrounds were largely C57BL/6J by SNP genotyping (Table. 
4). Surprisingly, IFNγ-primed macrophages from WT C57BL/6J mice 
and from each of the knockout strains responded similarly to C85 with 
a reduction in release of IL-10 (Fig. 4A, B, C left panel), increase in RNI 
(Fig. 4A, B, C middle panel) and increase in TNFα (Fig. 4A, B, C right 
panel). These results demonstrated that C85’s effects were PKR-
independent.  
 
Table 4. SNP genotyping of mice used in this study.  
Results are representative of two biological replicates. 
 
Type of strain Background 
PKR-regulatory domain KO mice  94.6% C57BL/6J 
PKR- kinase domain KO mice  97.3% C57BL/6J 
WT mice  99.8 % C57BL/6J 
PKR-regulatory domain KO mice on mixed 
background 
98.9% 
129S1/SvImJ 
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Figure 4. PKR deficiency or sufficiency on C57BL/6J background 
does not impact the effect of C85 on macrophage activation.  
A)   C85 reduces IL-10 and increases nitrite and TNFα in response to 
IFNγ in WT (B6) macrophages. 
B)   C85 reduces IL-10 and increases nitrite and TNFα in response to 
IFNγ in PKR-regulatory domain KO (B6) macrophages. 
C)   C85 reduces IL-10 and increases nitrite and TNFα in response to 
IFNγ in PKR-kinase domain KO (B6) macrophages. 
Results in (A) - (C) are means ± SEM of two independent 
experiments each performed in triplicate. p < 0.05 = *; p < 0.01 = 
**; p < 0.005 = ***; p < 0.001 = **** 
 
Macrophages from 129S1/SvImJ show enhanced macrophage 
activation in response to IFNg. 
 The foregoing results conflicted with those reported earlier with 
another strain of PKR regulatory domain knockout mice (Wu et al., 
2012). We suspected that those mice were not sufficiently 
 
 
 
39 
backcrossed.  The investigation leading back to the original laboratory 
notebooks revealed that the mice had not been backcrossed in the 
producing lab (Yang et al., 1995). SNP genotyping revealed that our 
colony, derived from breeders from the original lab, was 98.9% 
129S1/SvImJ. We then compared macrophages from these mice and 
from 129S1/SvImJ WT mice and observed that IFNγ induced little 
production of IL-10 in either case (Fig. 5A left panel). However, IFNγ 
alone induced production of RNI and TNFα in 129S1/SvImJ 
macrophages- whether WT or PKR-deficient— to levels as high as 
those produced by C57BL/6J macrophages exposed to IFNγ and C85 
(Fig.  B, middle panels). 
 
Similar Mtb burden in WT and PKR-deficient mice with a shared 
C57BL/6 background.   
 Finally, we infected PKR kinase domain knockout and WT mice 
with Mtb by low-dose aerosol infection. In order to minimize any 
differences in genetic background or microbiome, we used as parental 
strains WT C57BL/6J mice and PKR kinase domain knockout mice 
that were 97.3% C57BL/6J (Table 3), mated them, interbred their F1 
littermates, and genotyped the resulting F2 littermates to identify WT 
and homozygous PKR-deficient individuals. The latter two groups had 
indistinguishable pulmonary (Fig. 6A) burdens of Mtb at days 14, 29, 
57 and 120 post low-dose aerosol infection and indistinguishable 
splenic (Fig. 6B) burdens of Mtb at days 29, 57 and 120 post low-dose 
aerosol infection. 
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Figure 5. Macrophages from 129S1/SvImJ mice show enhanced 
macrophage activation in response to IFNg. 
A)   IFNγ does not induce the production of IL-10 and induces the 
production of nitrite and TNFa in WT (129S1/SvImJ) 
macrophages.  
B)   IFNγ does not induce the production of IL-10 and induces the 
production of nitrite and TNFa in PKR regulatory domain 
(129S1/SvImJ) macrophages.  
Results in (A) and (B) are means ± SEM of two independent 
experiments each performed in triplicate. p < 0.05 = *; ns = non-
significant 
 
 
 
 
 
 
Figure 6. Similar Mtb burden in WT and PKR-deficient mice with a 
shared C57BL/6 background.   
A)   CFU (colony forming units) burden in lung; B) CFU burden in 
spleen. Numbers of mice (n) = 3 for day 1; n = 4 for day 14; n = 5 
for days 29, 57 and 120. Data are means ± SEM 
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DISCUSSION 
 During our screen, we observed that some compounds were not 
active on isolated PKR but produced the desired phenotypes in BMMs 
(such as 2033, 2034 in Table 2), and some compounds active on 
isolated PKR did not produce desired phenotypes in BMMs (such as 
2044, 2045 in Table 2). We hypothesized that our inhibitors could be 
acting upstream of PKR.  
In addition, IC50 values were determined on human PKR, whereas we 
tested in mouse BMMs and a mouse model of Mtb infection. Between 
mouse and human PKR, there is 58% identity; the active site and ATP 
binding site are nearly identical. (Fig. 7) 
 
 
 
 
 
 
Fig 7. The similarity in domains between mouse PKR (Mus 
musculus) and human PKR (Homo sapiens). Source: Uniprot. org 
These inhibitors were screened against PKR before we identified 
that in the original study the phenotypes were due to strain 
dependency and not PKR. 
  This study rectifies a previous conclusion that was based on a 
misinterpretation of the strain backgrounds in knockout and control 
mice (Wu et al., 2012), and in so doing reinforces the importance of 
using mice with matched genetic backgrounds in studies based on 
gene disruption. The present work also illustrates that chemical 
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probes selected for their ability to inhibit a given kinase, even when 
found to be highly selective for that kinase, may nonetheless give 
phenotypes that are unrelated to inhibition of the kinase against 
which they were selected. The main conclusion of the present study is 
that PKR need not be considered as a target for HDT of TB.  
Another observation from this work is that BMMs of the 
129S1/SvImJ strain respond to IFNγ with greater production of RNI 
and TNFα than those of C57BL/6J origin. This observation extends 
earlier evidence that 129 strains and C57BL/6J strains produce 
different levels of IFNs and have different responses to other IFNs. For 
example, naïve 129Sv mice had higher levels of circulating 
plasmacytoid dendritic cells (DCs) than C57BL/6 mice (Asselin-Paturel 
et al., 2003). 129S7 mice produced higher levels of type I and type III 
IFNs and higher mortality when challenged with influenza virus than 
C57BL/6 mice (Davidson et al., 2014). Mice lacking the type I IFN 
receptor (IFNAR KO mice) on the C57BL/6 background fared 
comparably to WT C57BL/6 mice when infected with Mtb (Desvignes 
et al., 2012; Stanley et al., 2007), while IFNAR KO mice on the 129S2 
background succumbed much more rapidly than the WT controls 
(Dorhoi et al., 2014). The WT strains themselves respond differently to 
Mtb as well:  C57BL/6J mice are classified as highly resistant to Mtb 
and 129/SvJ mice as highly susceptible (Medina and North, 1998).  
        We do not know the mechanism for the strikingly different 
responses of 129S1/SvImJ BMMs and C57BL/6J BMMs to IFNγ. A 
comparison of the sequences of IFNg receptor genes Ifngr1 and Ifngr2 
in 17 inbred mouse strains (B et al., 2011; Keane et al., 2011) (Tables 
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5 and 6) mostly revealed intronic variants. These could conceivably 
affect alternative splicing, which in turn can impact expression level, 
or might impact downstream regulatory elements. We observed that in 
response to IFNg alone, WT 129S1/SvImJ produced 8-fold more Tnf 
expression and 70-fold more Nos2 expression and had reduced levels 
of Il10 expression compared to WT C57BL/6J mice (Fig. 8). We 
performed RNA-seq on RNA extracted from BMMs of these mice in the 
absence and presence of IFNg for 24 hrs.  
 RNA-seq analysis revealed that in the presence of IFNg, Ifngr1 
expression was lower and Ifngr2 expression was higher in 
129S1/SvImJ compared to C57BL/6J BMMs (Figure 9), but we do not 
know if these differences lead to differential responsiveness to IFNγ. 
 
 
 
 
 
 
 
Figure 8. In response to IFNg, WT129S1/SvImJ macrophages are 
more activated than WT C57BL/6J macrophages at a 
transcriptional level. Data representative of one experiment out of 
three.   
          Although the actions of C85 were not attributable to its 
inhibition of PKR, they remain of interest. Our current efforts are 
focused on identifying the functionally relevant targets inhibited by 
C85 and its congeners. We believe that we were on the right track for 
looking for compounds that increase nitrite and TNFa and decrease IL-
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10 as those changes might lead to improved TB control by the host 
(Discussed in Chapter 1). It is important to be guided by BMM 
phenotypes for the goal of creating more stable compounds having 
better bioavailability in vivo. We have developed potentially promising 
agents for HDT that we tested in mouse model of Mtb infection 
(Chapter 3). We also developed PKR inhibitors which could find use in 
the context of other diseases such as insulin resistance, 
neurodegeneration and cancer (Mouton-Liger et al., 2015; Nakamura 
et al., 2014; Pataer et al., 2009).  
 
 
 
 
 
 
 
 
 
Figure. 9. Ifngr1 and Ifngr2 gene expression plotted from RNA-seq 
data (n=3) obtained from BMMs treated with or without IFNg (10 
ng/ml) for 24 hr. 
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METHODS 
Mice  
Two types of targeted mutations in PKR have been reported in mice, 
deletion of PKR RNA-binding domain (Yang et al., 1995) and deletion of 
PKR catalytic domain (Abraham et al., 1999). Femurs from PKR RNA-
binding domain knockout mice were a gift from Dr. Robert Silverman 
(Lerner Research Institute, Cleveland, OH). Upon receipt, these mice 
were 94.6% C57BL/6J background, based on SNP typing by the 
Rockefeller University Genomics Resource Center. PKR catalytic 
domain knockout mice were a gift from Dr. Gokhan Hothamisligil 
(Harvard School of Public Health, Boston, MA). Upon receipt, these 
mice were 97.3% C57BL/6J background based on SNP genotyping. 
Experiments with BMM used femurs sent from the providing 
laboratories and control macrophages from C57BL/6J mice from The 
Jackson Laboratories, Bar Harbor, ME. For in vivo infection, we 
crossed the catalytic domain PKR knockout strain with C57BL/6J 
mice from The Jackson Laboratories to generate heterozygotes. The 
heterozygotes were interbred and the F2 littermates were genotyped. 
Knockout (KO) and WT mice from F2 generations were used further to 
expand the colony prior to use in the experiment.  
For genotyping, tails of mice were digested in 500 µl Tail Lysis Buffer 
(50 mM Tris pH 8.0, 100 mM EDTA and 100 mM NaCl) and 10 µl of 
Proteinase K (20 mg/ml) overnight in a water bath at 56° C. Digested 
tails were spun at 13000 rpm for 10 mins to remove debris. DNA was 
then precipitated with equal volume of isopropanol after spinning at 
13000 rpm for 5 mins. The pellets were air-dried and dissolved in TE 
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buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0). Illustra PureTaq Ready-
to-go beads were used for the reaction. PKR WT and KO mice were 
genotyped with PCR primers (KO - forward, 5′-
GGAACTTTGGAGCAATGGA-3′, reverse,  
5′-TGCCAATCACAAATCTAAAAC-3′; WT - forward, 5′-
TGTTCTGTGGCTATCAGGG-3′, reverse, 5′-TGACGAGTTCTTCTGAGGG-
3′) yielding a 240-base-pair (bp) WT DNA band and a 460-bp mutant 
DNA band after electrophoresis in 2% agarose gel in TAE buffer. The 
PCR reaction was run in a GeneAmp PCR System 9700 (Applied 
Biosystems) using initial denaturation at 94 °C for 3 mins, 38 cycles at 
94 °C 30s, 50 °C 30s, 72 °C 30s, final extension at 72 °C for 10 mins. 
 
Macrophages 
C57BL/6J adult (> 6 weeks and < 4 months) female mice were used 
for the culture of BMMs. Bone marrow cells were flushed from femurs. 
Cells were differentiated for 6 days in Petri dishes in Dulbecco’s 
minimal Eagle medium (DMEM) containing 1% HEPES, 0.29 g/L L-
glutamine, 1 mM sodium pyruvate, 10% fetal bovine serum (FBS) and 
20% L929 fibroblast-conditioned medium. Macrophages were collected 
on day 6 by incubation in 1 mM EDTA in PBS for 10 mins on ice, 
washed once with PBS and seeded into 48-well plates (Corning) 
overnight at density of 2.5´105 cells per well. Purified recombinant 
mouse IFNg (Roche) was used at 10 ng/ml in all studies.   
 
Mtb infection in mice 
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8 - 12-week-old WT and kinase domain KO female mice on C57BL/6J 
background were infected with about 100 CFU of Mtb H37Rv by using 
an Inhalation Exposure System (Glas-Col). Mid-log phase Mtb culture 
was grown in 7H9 broth (BD Biosciences) with BBL Middlebrook 
OADC Enrichment (Becton Dickinson) and   0.05% (vol/vol) Tween 
80 (Sigma-Aldrich) and washed once in PBS + 0.05% Tween 
80, centrifuged once at 120 g for 12 mins to prepare single cell 
suspension. The inoculum (5 ml, adjusted to an OD580 = 0.1-0.2 in 
PBS) was nebulized for 40 min. At indicated time points, mice were 
euthanatized and the lungs (all but not left lobe) and spleen were 
homogenized in 2 mls PBS (Bullet blender) and plated with and 
without serial dilution on 7H10-OADC agar containing 0.5 % glycerol. 
The plates were incubated at 37°C for 3 weeks for determination of 
colony-forming units (CFU). 
 
Measurements of Cytokines and RNI  
TNFa and IL-10 in culture supernatants were measured by ELISA 
(R&D Systems) according to manufacturer’s protocols, with values in 
cell-free medium subtracted. Assays were performed in triplicate for 
each experiment. RNI were measured as nitrite by mixing 50 µL of 
supernatant with 50 µL of Griess reagent prepared by mixing equal 
volumes of Griess Reagent 1 (2% sulphanilamide in 5% H3PO4) and 
Griess Reagent 2 (0.2% naphthylethylenediamine dihydrochloride). 
Absorbance at 550 nm was measured with sodium nitrite as standard. 
Nitrite content of cell-free medium was subtracted. 
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PKR Assay 
The assay was performed as reported (Bryk et al., 2011) 
 
Statistical Analysis 
PRISM 7.0 Graphpad software was applied for statistical analyses. 
Concentrations of cytokines and nitrite were statistically analyzed 
using two-way ANOVA comparing mean differences between groups 
treated ± IFNg . p-values < 0.05 were considered statistically 
significant. 
 
Contributions 
All experiments on isolated human PKR were performed by R. Bryk. 
The project on PKR screening was started in collaboration withR. Bryk.  
S. Mundhra cultured and plated all BMMs and performed all ELISAs 
and most of the nitrite assays.  
R. Bryk and S. Mundhra jointly optimized assays. S. Mundhra 
identified that the discrepancy between mouse backgrounds and 
phenotypes were mouse background dependent. 
X. Jiang and S. Mundhra jointly performed Mtb infection in mice and 
S. Mundhra analyzed and graphed the data. 
C. Nathan helped with editing a part of this chapter that was written 
as a manuscript. 
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small molecules in host-directed 
therapy of TB 
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CHAPTER 3 
INTRODUCTION 
 
Host-directed, immunomodulatory treatment of tuberculosis 
(TB) has shown promise in several studies that used different 
approaches such as cytokine supplementation (Condos et al., 1997), 
vitamin supplementation (Wallis and Zumla, 2016), DNA vaccination 
(Lowrie et al., 1999), heat-killed Mycobacterium vaccae (Johnson et al., 
2000), therapeutic multi-stage vaccination to control reactivation 
(Aagaard et al., 2011) and targeted siRNA treatment (Rosas-Taraco et 
al., 2009) among others. Some of these approaches have been 
demonstrated to be effective against drug-resistant Mtb strains in 
murine models of TB (Bertholet et al., 2010; Okada et al., 2009) and in 
TB patients (Condos et al., 1997). In the recent years, host-directed 
small molecules have shown potential in reducing bacterial burden in 
various models of mycobacterial infection. Such inhibitors were 
directed against phosphodiesterase (PE) type four (Koo et al., 2011), 
ABL tyrosine kinase family (Napier et al., 2011, 2015), PE types three 
and five (Maiga et al., 2012), HMG-CoA reductase i.e. statins (Parihar 
et al., 2014), AMPK activators i.e. metformin (Singhal et al., 2014), and 
drugs augmenting prostaglandin E2 levels (Mayer-Barber et al., 2014),  
 In this chapter, we investigate the potential of small molecules 
C2062 and C85, identified in the screen described in Chapter 2, as 
agents for host-directed therapy (HDT) of TB and as tools to identify 
the pathways involved in enhanced activation of macrophages. 
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RESULTS 
Characterization of actions of small molecules in uninfected 
macrophages 
 As described in Chapter 2, we screened over 150 inhibitors from 
the CGH library on bone marrow-derived macrophages (BMMs) in the 
presence of IFNg for increases in production of RNI and TNFa and 
decrease in production of IL-10 compared to IFNg alone (Fig. 1 chapter 
2). Concentration-response curves for the two small molecules C85 
and C2062 are shown in Figure 1. C85 produced nitrite and TNFa at 
10 µM and 30 µM and reduced IL-10 as well at higher concentrations 
(Figure 1A; left, middle and right panels respectively). C2062 produced 
nitrite and TNFa 5 µM and 10 µM and lowered IL-10 at those 
concentrations (Figure 1B; left, middle and right panels respectively). It 
was toxic at 30 µM. To investigate further, we sought to determine 
whether these small molecules could enhance these mediators at a 
transcriptional level. To this end, we primed BMMs with IFNg for 24 hr 
and treated with compounds for 6 hr at different concentrations prior 
to RNA isolation.C85 increased expression of Nos2 by 170-fold 
compared to IFNg alone. The highest expression of Tnf and lowest 
expression of Il10 was observed at the highest concentration of 10 µM 
of C85 (Fig. 1C). C2062 also enhanced Nos2 expression by 750-fold 
and Tnf expression by 6-fold compared to vehicle. In addition, C2062 
abrogated Il10 expression completely compared to vehicle (Fig. 1D). 
However, in both experiments, we observed that vehicle (DMSO) alone 
was reduced Il10 gene expression. This could be attributed to DMSO 
having an effect on Il10 transcription. However, compared to vehicle, 
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we did see a decrease in Il10 gene expression at 10 µM for both 
compounds suggesting that this effect was compound-dependent and 
not just due to DMSO. It is to be noted that a rise in transcripts need 
not result from increased transcription. It could be due to reduced 
mRNA decay. A rise in protein levels could be due to increased 
transcription, decreased proteasomal degradation or increased 
cytokine secretion. Those studies were not performed in this 
dissertation work. 
We wanted to further investigate whether these small molecules 
increased the production of other pro-inflammatory cytokines. We 
observed that C2062 and C85 increased production of IL-12p40 at 10 
µM while the inactive control, C2753 did not. IL-12p40 has been 
implicated to be critical in control of Mtb (Méndez-Samperio, 2010). 
The continuous presence of IL-12 is required to maintain pulmonary 
Th1 immune response in chronic tuberculosis infection. In addition, it 
has been shown that in patients with Mendelian susceptibility to 
mycobacterial disease, the disease is caused as a result of IL-12B1 
and IL-12p40 deficiency among several other factors (Filipe-Santos et 
al., 2006). Taken together, our data show that these small molecules 
can increase production of mediators important for TB control. 
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Fig. 1 C85 and C2062 enhance macrophage activation at the 
mRNA and protein product level. Concentration-response curve of 
C85 (A and C) and C2062 (B and D) and its impact on IL-10 reduction, 
nitrite and TNFa production at a protein level and transcriptional level. 
WT BMMs were primed with IFNg (10 ng/ml) for 24 hr then treated 
with compounds for 48 hr. Results are means ± SD of triplicates in one 
experiment representative of two.  
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Fig. 2 C85 and C2062 increase production of IL-12 p40 in the 
presence of IFNg. Results are means ± SEM of triplicates in one 
experiment representative of two independent experiments. 
 
 Experiments described above were conducted with IFNg as the 
sole stimulus. We wanted to investigate whether small molecules can 
reduce IL-10 produced by other stimuli. We tested two stimuli - 
lipopolysaccharide (LPS) and heat-killed Mtb (HKMT). Both are known 
to be potent inducers of IL-10 (Barsig et al., 1995; Saraiva and 
O’Garra, 2010). We observed that after 24 hr stimulation with 10 
ng/ml of LPS, macrophages produced massive amounts of IL-10, and 
the addition of 2062 5 µM reduced these levels (Fig. 3A). C2062 also 
reduced IL-10 produced by HKMT stimulation (Fig. 3B). IL-10 levels in 
the presence of IFNg remained low (Fig. 3A and 3B), as IFNg is known 
to antagonize the production of IL-10 (Hu et al., 2006; Saraiva and 
O’Garra, 2010). Therefore, C2062 was able to decrease IL-10 
production in the presence of a TLR4 agonist (LPS) and a TLR2 agonist 
(HKMT), suggesting it was targeting a generic IL-10 induction pathway. 
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Figure 3. C2062 reduces IL-10 in response LPS and HKMT.  
(A)  BMMs treated with 1, 10 and 100 ng/ml of LPS for 24 hr +/- 5 µM 
C2062 added for 24 hr. IL-10 levels measured in the supernatants. 
(B)  IL-10 produced by BMMs when stimulated with HKMT for 24 hr +/- 
C2062. 
  
 IL-10 is known to antagonize TNFa production (Bogdan et al., 
1991) in macrophages. Moreover, inhibition of IL-10 production has 
been shown to correlate with increased TNFa expression in human 
monocytes (Donnelly et al., 1995). We sought to investigate whether 
TNFa production was increasing in response to decreased IL-10 levels. 
We tested 3 compounds - C85, C2062 and an inactive control 2753 in 
a concentration - dependent manner in IL10-/- BMMs derived from IL-
10 KO mice compared to WT mice (both on C57BL/6J background) 
(Fig. 4A). We observed that the WT and IL10-/- macrophages produced 
TNFa and nitrite to similar levels at 48 hours (Fig. 3B), suggesting that 
these effects were independent of IL-10 reduction. However, this 
experiment was performed only at one time-point – 48hr and it 
possible that these effects could be different at early or later time-
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points. Hence, these results suggested that nitrite and TNFa elevation 
and IL-10 reduction are separate pathways. 
 
Additional steps towards understanding the mechanism of C2062 
and C85 in uninfected macrophages. 
 To further understand what pathways could be involved in these 
phenotypes, we performed RNA sequencing on RNA extracted from 
macrophages treated with these small molecules. We sent RNA 
isolated from macrophages treated at 3 time-points – 1 hr, 2 hr and 3 
hr with C85 and C2062 at 10 µM which increased Tnf and Nos2 (Fig. 
5A and Fig. 5B) gene expression and reduced I10 (Fig. 5C) expression. 
C2753 was used as an inactive control. 
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Figure 4. The increase in nitrite and TNFa is IL-10 independent. 
A)  Schematic representation of the experimental outline 
B)  Concentration-response curve of C85, C2062, and C2753 and 
its impact on nitrite and TNFa production by WT BMMs primed 
with IFNg (10 ng/ml) for 24 hr then treated with compounds for 
48 hr. Results are means ± SD of triplicates in one experiment 
representative of two 
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Fig. 5 Gene expression profile of samples treated with C85, 
C2062, and C2753 at 1, 2 and 6 hr and sent for RNA-sequencing. 
A)   Expression of Nos2 gene 
B)   Expression of Tnf gene 
C)   Expression of Il10 gene 
Results are representative of four independent experiments. 
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Figure 6. The methodology used for RNA-seq analysis An outline of 
RNA-seq analysis is shown as a schematic. 
 
 We hypothesized that at early time-points (1 hr and 2 hr), genes 
that overlap with increased expression between the C85 and C2062 
but are not present in C2753 might be key candidates in the pathway 
being targeted. The premise is that, if the small molecules were 
inhibiting certain enzymes such as kinases, the cell would try to 
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compensate by upregulating them. We also hypothesized that at 6 hr 
time point, there would be an amplification of the effects caused by the 
small molecule treatment, such as secondary effects of changes in 
gene expression caused by the primary effects. Hence, the 6 hr time-
point would be ideal to observe the changes in pathways being 
dysregulated. Supplementary Figure 1 and 2 give a list of the common 
genes upregulated and downregulated respectively between C85 and 
C2062. Supplementary Figure 3 shows the key pathways that were 
upregulated at 6 hr. We observed that many pro-inflammatory 
pathways common between C85 and C2062 were upregulated. As 
expected, C2753 did not have an effect on any of those pathways. 
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Fig. 7 Salt-inducible kinase 1 is the only kinase upregulated by 
C85 and C2062 treatment at 1 hr.  
(A)  Venn diagram showing number of common genes upregulated 
by C85 and C2062 (highlighted in a red box) 
(B)  List showing names of genes upregulated (from A) 
(C)  Fold change values of Sik1 at indicated time-points compared to 
their respective vehicle control.  
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 For the purpose of this chapter, we will highlight the genes that 
we picked for further study. As we had shown earlier that 85 (Chapter 
2, Fig. 1A) and 2062 (data not shown), both inhibited PKR in an ATP-
competitive manner, hence we thought the target of these small 
molecules could be a kinase. The only kinase which was upregulated 
in macrophages treated with C85 and C2062 at 1 hr, but not so in 
C2753, was salt-inducible kinase 1 (Sik1). Our data is also shown in a 
Venn diagram (Fig. 7A) along with the list of genes common between 
C85 and C2062 (Fig. 7B). Treatment with C85 and C2062, but not the 
inactive control compound C2753, upregulated expression of Sik1 
when compared to vehicle, up to five-fold by 1 hr and nine-fold by 2 
hr. These results indicated that Sik1 could be a potential target. 
 
Table 1. NUAK1 and ARK5 (AMPK related kinase were inhibited by 
C85 and C2062 but not by C2753. All compounds were tested at 3 
µM for kinase selectivity in assays performed by Life Technologies' 
SelectScreen® Profiling Service. The values are mean % activity 
remaining. Kinases are highlighted in red that were inhibited to the 
point that <20% activity remained.   
 
 
 
 
 
 
 
 
A.
B.
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 Among the other genes in Figure 7B- rhov encodes Rho family 
GTPases and is not expressed in humans; ppp1r15a encodes protein 
phosphatase 1 regulatory subunit 15A that recruits the phosphatase 
PP1 that dephosphorylates eIF2a; ddit3 encodes DNA damage 
inducible transcript 3 which is a multifunctional transcription factor 
in ER stress response; osgin1  encodes oxidative stress induced growth 
inhibitor 1 which is known to regulate cell growth and tumor 
formation; chac1 encodes glutathione specific gamma 
glutamylcyclotransferase 1 which promotes neurogenesis in embryos 
and bhlhe40 encodes a basic helix-loop-helix protein expressed in 
various tissues. As inhibiting any of these did not seem useful in the 
context of TB infection, and from our studies described in Chapter 2, 
we hypothesized that one of the targets could potentially be a kinase. 
Therefore, we decided to look into the literature to better understand 
the relationship between SIK1 and NUAK1. NUAK1 is a 
serine/threonine-protein kinase involved in various processes such a 
cell adhesion, cell proliferation, regulation of cell ploidy and 
senescence and tumor progression (Sun et al., 2013). We found that 
both were members of the same family – AMPK or 5’ Adenosine Mono 
Phosphate-activated kinase family (Fig. 8). This family of kinases can 
be regulated by an upstream kinase known as liver kinase B1 (LKB1), 
which is also a tumor suppressor (Hardie and Alessi, 2013).  
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Fig. 8 Members of AMPK and AMPK related kinase family (ARK) 
Adapted from (Hardie and Alessi, 2013) 
 
 We sent our small molecules, C2062, and C2753, to be profiled 
against all kinases in the AMPK family at DiscoveRx Kinome Profiling 
Service. Surprisingly, we observed that C2062 inhibited both NUAK 
1/2 and the master regulator – LKB1 (Fig. 9). This inhibition of the 
AMPK pathway suggested that if C2062 was inhibiting the master 
regulator LKB1, the downstream kinases would most likely also be 
inhibited.  
 Further literature research showed that BMMs from mice that 
had a myeloid-specific deletion of LKB1 produced more pro-
inflammatory enzymes and cytokines in response to LPS, compared to 
their littermate WT controls. This was due to LKB1 inhibition of LPS-
induced NF- kB activation in macrophages (Liu et al., 2015). 
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Additionally, AMPKα1 has been shown to be crucial for phagocytosis-
induced macrophage skewing from a pro- to anti-inflammatory 
phenotype at the time of resolution of inflammation (Mounier et al., 
2013). AMPK a -/- macrophages were shown to be incapable of 
switching to an M2 (anti-inflammatory) phenotype from an M1 (pro-
inflammatory phenotype).  
 These results indicated that C2062-mediated induction of nitrite 
and TNFa could be due to LKB1 inhibition. We investigated this 
further in the context of Mtb-infected macrophages (described in the 
subsequent section). 
 C85 and C2062, both produced large vacuoles in the presence of 
IFNg (Fig. 10B and Fig. 10C) compared to untreated BMMs (Fig. 10A). 
Literature search and experiments conducted by Ruslana Bryk 
suggest that these inhibitors could be targeting PI3 kinases, 
specifically PIKfyve (a FYVE finger containing inositide kinase). PIKfyve 
inhibition is known to result in vacuolar phenotype in macrophages 
(Kim et al., 2014). We sought to investigate if inhibition of PIKfyve 
would also give the phenotypes of nitrite and TNFa elevation and IL-10 
reduction. We tested two different inhibitors of PIKfyve that are 
currently available: YM201636 (IC50 = 33 nM), a widely used PIKfyve 
antagonist (Jefferies et al., 2008; Sbrissa et al., 2012) and MF4 (IC50 = 
23 nM), a compound chemically related to YM201636, differing in an 
amino group on the pyrimidine ring (Kim et al., 2014). We also used an 
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Fig. 9 Profiling of C2062 and C2753 against all kinases belonging 
to the AMPK family. Both compounds were tested at 3 µM for kinase 
selectivity in assays performed by DiscoveRx KINOMEscan Profiling 
Service. The values are mean % activity remaining, calculated by 
subtracting mean % inhibition from 100 %. Kinases that were 
inhibited to the point that <20% activity remained highlighted in a red 
box.  R. Bryk conceived the idea and sent out samples for profiling 
service. 
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Fig. 10 C85 and C2062 produce vacuoles 24 hr post treatment.  
(A)  BMMs in absence or presence of IFNg (left and right panels 
respectively). No compound treatment is abbreviated as NT. 
(B)  BMMs treated with C85 (10 µM) in absence or presence of IFNg 
(left and right panels respectively) 
(C)  BMMs treated with C2062 (5 µM) in absence or presence of IFNg 
(left and right panels respectively). All images have been taken 
at a magnification of 20X.
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inactive congener of MF4 called MF2 as an inactive control. We 
observed that both MF4 (Fig. 11A) and YM201636 (Fig. 11B) increased 
nitrite and TNFa and reduced IL-10 in the presence of IFNg at 3 µM 
and 10 µM. MF2, the inactive control did not do so. These effects were 
enhanced when combined with 1 µM C2062 treatment (Reported by R. 
Bryk, data not shown). 
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Fig. 11 MF4 and YM201636 enhance macrophage activation. 
Concentration-response curve of MF4 (A) and YM201636 (B) and the 
inactive congener of MF4 – MF2 (C) and its impact on nitrite and TNFa 
production and IL-10 reduction. WT BMMs were primed with IFNg (10 
ng/ml) for 24 hr then treated with compounds for 48 hr. Results are 
means ± SEM of triplicates in one experiment.  
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 These results prompted us to test C2062 in a DiscoveRx kinase 
binding assay against PIKfyve along with a congener (considered to be 
a control because it did not produce the three phenotypes when tested 
at 10 µM). Their dissociation constants’ (Kd) were reported to be 260 
nM and 1400 nM, respectively.  
 Since our phenotypes are only observed at concentrations far 
above the Kd’s for PIKfyve, we suspect that the desired phenotypes 
result from a combination of PIKfyve inhibition and less potent 
inhibition of some other target(s) common to the inhibitors, MF4 and 
YM201636, even though the core chemophore of C2062 is different 
from that of MF4 and YM201636. We believe that PIKfyve inhibition is 
necessary but not sufficient to attain BMM phenotypes. We tested 
C2062 at 1 µM, a concentration at which no vacuoles or other 
phenotypes are observed, in combination with MF4 (1 µM), a PIKfyve 
inhibitor producing vacuoles but no other phenotypes at 1 µM. We 
observed BMM phenotypes with 2062/MF4 co-treatment. This 
suggests that when C2062 is used alone, it inhibits other targets at 
lower concentrations. However, it takes higher concentrations for 
C2062 to inhibit PIKfyve and trigger manifestation of the phenotypes. 
Taken together, these results suggest that there are targets and/or 
signaling pathways inhibited in common by MF4, YM203616, and 
C2062, but a different concentration is required by the above 
mentioned small molecules to selectively inhibit PIKfyve vs the other 
target(s). 
 Having characterized these small molecules in uninfected 
macrophages, we next sought to study the effects of C2062 in Mtb-
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infected macrophages and to further study if the enhanced activation 
of macrophages with C2062 would lead to reduced Mtb burden if used 
in combination with known antibiotics. 
 
 
Characterization of actions of small molecules in Mtb-infected 
macrophages 
We next wanted to study the effect of our small molecules in the 
context of Mtb infection. First, we infected BMMs primed with IFNg (10 
ng/ml) for 24 hr and then infected them with Mtb strain H37Rv for 4 
hr. We treated the infected macrophages with the small molecules and 
monitored for the bacterial burden on days 3 and 5 post-treatment 
(Fig. 13).  We tested C2062 alone and in combination with two 
antibiotics – rifampicin (Rif) and isoniazid (INH). We also tested 
MRT67307 (MRT), which is an inhibitor of LKB1, and therefore inhibits 
the AMPK pathway. As mentioned previously, we had observed that 
MRT-mediated inhibition of LKB1 leads to a pro-inflammatory 
phenotype. We wanted to test this in the context of Mtb infection. We 
also tested metformin, which is known to activate the AMPK pathway. 
 
We observed that MRT alone slightly reduced Mtb burden, and MRT + 
rif seemed to hasten the reduction in bacterial burden compared to rif 
alone. Metformin did not reduce CFU burden alone, nor did it improve 
the reduction as seen with rif (Fig.13 A and B). This is contrary to 
what has been reported (Singhal et al., 2014). MRT seemed to enhance 
the control of Mtb in presence of IFNg (Fig. 13B). C2062 seemed to 
reduce bacterial burden slightly more when treated in combination 
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with rif (13. C and D) and isoniazid (13 E and F) suggesting that it 
would be an ideal candidate for HDT. 
 
Day$5$post$
treatment
Treatment(with(compounds
Day$0
Infect'BMDMs'with'
Mtb (!/+#IFNγ)"
M.O.I%0.1
Add#media#after#4#hr
Plate&cells&for&CFU,%nitrite%on%
supernatants)and$observe'cell'
morphology) by)microscopy
Day$1
post%infection
Replace'media&
with%compounds)
(+/! IFNγ)
Day$3$post$
treatment
 
 
 
Fig. 12 Schematic representation of the experimental outline 
 
We observed cell morphology and in Mtb-infected macrophages, MRT 
did not form vacuoles (Fig. 14 C and D) unlike C2062 (Fig. 14 B and 
E). Cells were alive up to day 5 post compound treatment, suggesting 
that the compounds were not toxic in the presence of rif. The presence 
of vacuoles indicate that the compound is not metabolized. 
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Fig. 13 Impact of small molecules enhancing macrophage 
activation on the bacterial burden in conjunction with antibiotics. 
The impact of MRT and metformin on Mtb burden in macrophages 
without (A) and with IFN g (B) in conjunction with rif. The impact of 
C2062 and rif on Mtb burden in macrophages in the absence (C) and 
in the presence of IFNg (D). Impact of C2062 and isoniazid on Mtb 
burden in macrophages in absence (E) and in the presence of IFN g (F). 
Results in A – D are means ± SEM of triplicates in one experiment 
representative of two independent experiments. 
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 We also observed that MRT greatly increased nitrite production 
(Fig. 15) in Mtb-infected macrophages compared to C2062 alone on 
days 3 and 5 post-treatment. This could be the reason why it led to 
better control of Mtb as observed in Fig. 14 A and B. 
 
DMSO%+%IFNγ 2062$+$IFNγ
2062$+$Rif$+$IFNγRif$+$IFNγ
MRT$+$IFNγ
MRT$+$Rif$+$IFNγ
A. B. C.
D. E. F.
 
 
Fig. 14 Images of cell morphology of Mtb-infected macrophages 
day 5 post treatment. Images taken at 20X maginification. 
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Fig. 15 MRT and C2062 greatly enhance nitrite production in IFNg 
treated BMMs day 3 and day 5 post treatment in Mtb-infected 
macrophages. Results are means ± SEM of triplicates in one 
experiment representative of two independent experiments. 
 
 We repeated the co-treatment experiment of 5 µM C2062 along 
with 0.5 µM Rif at three different time-points and observed a 
statistically significant increase in reduction of Mtb burden when 
C2062 was used in combination with rif compared to rif alone. (Fig. 
16). To rule out the effects of C2062 on Mtb, we performed Minimal 
Inhibitory concentration assays against Mtb in replicating conditions 
and observed that C2062 had no effect on Mtb, suggesting that it was 
reducing Mtb burden due to its effects on macrophage activation. 
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Fig. 16 C2062 reduces bacterial burden in combination with rif 
compared to rif alone in IFNg treated macrophages. Results are 
means ± SEM of triplicates in one experiment representative of three 
independent experiments. 
 
 Taken together, our data show that C2062 is a potential 
candidate for HDT in the context of Mtb infection in vitro. We next 
decided to investigate this further in a mouse model of Mtb infection. 
 
Characterization of C2062 in Mtb-infected mice  
 Based on the screen described in Chapter 2 (Fig. 2), we 
identified five inhibitors (C2071, C2004, C55, C2062, C2011) that 
enhanced macrophage activation i.e. increased nitrite and TNFa 
production while reducing IL-10 (Fig 17). These five inhibitors showed 
good pharmacokinetic properties when administered to mice 
(Performed by our collaborators at CGH and University of Cape Town).  
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Fig 17. Small molecules that enhance macrophage activation in 
vitro. The impact of lead inhibitors on nitrite and TNFa production 
and IL-10 reduction in WT BMMs primed with IFNg (10ng/ml) for 24 
hr and then treated with indicated compound for 48 hr. (Left; middle 
and right panels respectively). Results are mean ± SEM representative 
of one of two experiments, each performed in triplicate.  
 
 We tested C55, C2011, C2062, C2071, and C2004 in a mouse 
model of Mtb infection (Fig. 18A). Two compounds, namely C2011 and 
C2062 lowered mean CFU burden by 0.5 log10 (Fig. 18B). Individual 
mice treated with C2011 or 2C062 had a multi-log reduction in 
bacterial burden in the lung (Fig. 18C). C2011 lowered mean CFU 
burden by 2.5 log10 mice in spleen and two mice treated with C2011 
and one mouse treated with C2062 had no detectable CFU burden in 
spleen (Fig. 18D). C2071 was dosed at 30 mg / kg (mpk). C2004 and 
C55 had insoluble deposits of the compound in the peritoneum. 
C2011 treatment in mice elevated nitrate + nitrite in lungs (Fig. 18E). 
No elevation of nitrate + nitrite was seen in the serum of mice treated 
with C2011 and C2062 (data not shown). However, both compounds 
elevated TNFa levels in lung homogenates (Fig. 18E). There was no 
exacerbation of inflammatory pathology in the lungs, as evident from 
H&E stained sections of the lung (Fig. 18G)	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Figure 18. C2011 and C2062 reduce bacterial burden in vivo in a 
mouse model of Mtb infection and do not exacerbate 
inflammatory pathology in lung. 
A.   Experimental design of the infection and compound treatment. 
N=5 per group 
B.   C2062 and C2011 reduce bacterial burden day 56 post infection 
C.   CFU burden in the lung and  
D.  CFU burden in the spleen of individual mice on day 56 post-
infection. Data represented as Mean with n=5 mice per group. * 
indicates no CFU recovered in spleens of 2 mice treated with 
C2011 and 1 mouse treated with C2062 
E.   Nitrate + nitrite levels in lung homogenates  
F.   Levels of TNFa in lung homogenates 
G.  Histopathology of lungs with H&E staining of Vehicle (top panel) 
and C2062 (bottom panel) treated mice.  
All results are represented as mean in one experiment. X.Jiang 
performed the infection and compound treatment. S.Mundhra and 
R. Bryk analyzed and graphed the data. 
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C2062 reduced Mtb burden by 0.5 log10, which is the usual reduction 
reported by groups studying HDT (Napier et al., 2011; Singhal et al., 
2014). Since C2062 inhibited fewer kinases than C2011 in a kinase 
selectivity panel conducted at Celgene, we decided to repeat the mouse 
infection experiment with C2062 (Fig. 19A). In the repeat experiment, 
the mean CFU burden in the lung of 2062-treated mice on day 56 
post-infection was lower compared to vehicle control group (Fig. 19B) 
and all five mice showed reduced bacterial burden in spleen (Fig. 19C) 
compared to vehicle control group. In this experiment, we wanted to 
study the impact of C2062 on immune cell types in vivo. We observed 
that C2062-treated mice had an increase in the percentage of 
neutrophils (Fig. 19D) in lung draining lymph nodes as marked by 
Ly6ChiLy6Ghi cells when gated on CD11b+ CD45+ cells. C2062-treated 
mice also showed an increase in the percentage of iNOS producing 
myeloid cells as marked by iNOS+Cd11b+ cell population (Fig. 20E) 
and an increase in the percentage of TNFa producing myeloid cells as 
marked by TNFa+CD11b+ cell population (Fig. 19F) in lung draining 
lymph nodes. This increase directly correlated with a decrease in CFU 
burden. The mice in the C2062 treated group that had higher 
percentage of neutrophils (Fig. 19G), iNOS producing myeloid cells 
(Fig. 19H) or TNFa producing myeloid cells (Fig. 19I) had reduced CFU 
burden compared to their counterparts. These results suggest that the 
phenotypes of enhanced macrophage activation correlate with 
improved clearance of Mtb. Similar trends were observed in broncho-
alveolar lavage fluid (BALF), though statistically insignificant (Fig. 20 
A,B,C). Hence, C2062 was shown to have a pharmacodynamic effect. 
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Figure 19. C2062 reduces bacterial burden in vivo in a mouse 
model of Mtb infection and this reduction directly correlates with 
increases in neutrophils, TNFa+ and iNOS+ myeloid cells. 
Experimental design of the infection and compound treatment.  
CFU burden in lung and (C) CFU burden in spleen of individual  
mice on day 56 post-infection. Data represented as Mean with n=5 
mice per group. (D) Percentage of neutrophils (E) Percentage of myeloid 
cells producing iNOS and (F) Percentage of myeloid cells producing 
TNFa in Vehicle and C2062 treated mice. Representative FACS plots 
(middle panels) and quantification (far right panels). Correlation 
between CFU burden in 2062 treated mice and (G) Percentage of 
neutrophils (H) Percentage of iNOS+ myeloid cells and (I) Percentage of 
TNFa+ myeloid cells. Results in B are represented as Mean with n=5 
mice per group. Results in D, E and F are Mean ± SEM. X.Jiang and S. 
Mundhra performed the infection. X. Jiang treated mice with the 
compound. S.Mundhra analyzed and graphed the data. 
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Figure 20. The impact of 2062 treatment on cell types in vivo in 
BALF. (A) iNOS+ myeloid cells and (B) TNFa+ myeloid cells. n=4 in 
vehicle treated and n-5 mice in 2062-treated group. All results are 
represented as mean +-SEM in one experiment. 
 
 Despite an increase in pro-inflammatory mediators, C2062 did 
not exacerbate immunopathology in the lung. H&E stained sections of 
lung were evaluated by a pathologist in a blinded manner (Sebastien 
Monette at MSKCC Laboratory of Comparative Pathology). The 
inflammation score was similar between the two groups of mice (Fig. 
21A). Histopathology images of lung sections from representative mice 
of the vehicle and C2062-treated groups are shown (Fig. 21B). We also 
observed a significant increase in pro-inflammatory cytokines such as 
IL-12p70 (Fig. 21C), IFNg (Fig. 21D) and IL-6 (Fig. 21E) in lung 
homogenates from C2062-treated mice. We also observed a slight 
reduction in IL-10 (Fig. 21F) although this was not statistically 
significant. These results demonstrate, again, the pharmacodynamic 
effects of C2062. 
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Figure 21. C2062 increases pro-inflammatory cytokines in the 
lung without exacerbating immunopathology. 
(A). Inflammation score on histopathology of lungs from Vehicle and 
C2062 treated mice. Score based on extent (size and no. of foci) of 
inflammatory lesions: 0 = No lesions; 1= Minimal inflammation; 2 = 
Mild inflammation; 3 = Moderate inflammation; 4 = Marked 
inflammation. (B) Representative images of histopathology of lungs 
with H&E staining of Vehicle and C2062 treated mice.  
Levels of (C) IL-12p70, (D) IFNg, (E) IL-6 and (F) IL-10 in lung 
homogenates from Vehicle and C2062 treated mice, d56 post infection. 
n=4 in vehicle treated and n-5 mice in 2062-treated group. All results 
are represented as mean +-SEM in one experiment. 
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Figure 22. C2062 in combination with rif reduces bacterial burden 
in vivo in a mouse model of Mtb infection. (A) Experimental design 
of the infection and compound treatment. (B) CFU burden in the lung 
and (C) CFU burden in the spleen of individual mice on day 66 post-
infection. Data represented as mean with n=5 mice per group. (D) 
Percentage of myeloid cells producing iNOS in lung draining lymph 
nodes (E) Percentage of myeloid cells producing TNFa in lung draining 
lymph nodes (F) Percentage of neutrophils in lung draining lymph 
nodes. (G) Percentage of myeloid cells producing iNOS in the lung (H) 
Percentage of myeloid cells producing TNFa in the lung (I) Percentage 
of neutrophils in the lung. 
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Since C2062 showed efficacy in vivo in reducing bacterial burden, we 
decided to test it in conjunction with rifampicin (rif), a well-known 
antibiotic against Mtb, for proof of concept of HDT as an adjunctive 
treatment for TB. As rif is administered orally, CGH changed the 
formulation of C2062 to be given by oral gavage. We selected 3 doses 
for administration ± Rif (10 mg/kg): 10 mg/kg, 30 mg/kg and 75 
mg/kg. The time-points for harvest are indicated in Fig. 22A. We 
observed 3/5 mice in 2062-10 mg/kg group, 4/5 mice in 2062-30 
mg/kg group and 2/5 mice in 2062-75 mg/kg group reduce bacterial 
burden in conjunction with rif, compared to rif alone. However, we did 
not see any decrease in C2062 alone groups (all three doses) compared 
to the vehicle group (Fig. 22B). All rif treated groups had reduced 
bacterial burden in the spleen to similar amounts (Fig. 22C). 
 We observed a slight increase in the percentage of iNOS+ 
myeloid cells in lung draining lymph nodes (Fig. 22D) in 2062-10 mpk 
and 2062-30 mpk groups but not so in the lung (Fig. 22G). We 
observed a slight increase in the percentage of TNF a+ myeloid cells 
(Fig. 22H) and the percentage of neutrophils in lung of 2062-10 mpk 
group. The variability in the percentage of immune cell populations 
could be attributed to the differences in exposure of the compounds in 
mice when administered by oral gavage as compared to intraperitoneal 
(as in the previous experiment). We are currently investigating this and 
are in the process of repeating it. 
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DISCUSSION 
 
 We have shown that the phenotypes of enhanced macrophage 
activation – namely an increase in nitrite and TNFa, accompanied a 
reduction in IL-10 does lead to improved clearance of Mtb, both in vitro 
in BMMs and in vivo in mice. We believe that these pathways are 
critical for the control of Mtb as shown by the direct correlation 
between the reduction in bacterial burden and an increase in the 
percentage of neutrophils and CD11b+ iNOS+ TNFa+ cells in lung 
draining lymph nodes and bronchoalveolar lavage fluid. As mentioned 
in Chapter 1, neutrophils can play a dual role in Mtb infection and in 
our model system, they seemed to playing a beneficial role. 
 
 Although we are not sure of the exact target of C2062, we do 
know that it does inhibit LKB1, a master regulator of AMPK pathway. 
It will be interesting to infect BMMs from myeloid-specific knockout 
mice of LKB1 or challenge those mice with Mtb infection. We would 
speculate that, due to the extreme pro-inflammatory phenotype, the 
bacterial burden would be reduced. However, these mice are known to 
have severe lung damage, when challenged with LPS, due to increase 
in pro-inflammatory mediators (Liu et al., 2015). Hence, targeting 
LKB1 alone in the context of TB will not be feasible, as Mtb infection 
causes liquefaction of lungs in patients. The AMPK complex 
coordinates glucose metabolism with fatty acid oxidation to regulate 
energy availability (Xiao et al., 2011). In macrophages, AMPKa1 is 
predominantly expressed, and AMPKa2 is negligible (Kumase et al., 
2016). The role of AMPK in myeloid lineage, mainly during pathogen 
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specific immune responses are not well characterized. It has been 
proposed that myeloid-derived AMPK contributes toward the IL-4 
driven pathway that promotes M2 polarization and as loss of AMPKa1 
in myeloid cell exacerbated lung tissue injury in the context of 
hookworm infection (Nieves et al., 2016). AMPKa1 has been shown to 
be crucial for phagocytosis-induced macrophage skewing from a pro- 
to anti-inflammatory phenotype during resolution of inflammation in 
the context of skeletal muscle regeneration, as AMPKa1 deficiency led 
to a decrease in macrophage phagocytic activity (Mounier et al., 2013). 
Hence, developing an AMPKa1 specific inhibitor would not be 
beneficial in the context of Mtb infection. Moreover, AMPK activators 
such as Metformin have been implicated as an HDT agent for TB 
(Singhal et al., 2014) 
  In addition, targeting PIKfyve alone also would be futile as 
PIKfyve inhibition is known to reduce the degradative capacity of 
phagosomes. PIKfyve, likely through phosphatidylinositol-3,5-
bisphosphate synthesis, plays a critical role in endolysosomal and 
phagosome maturation in macrophages. As endolysosomal and 
phagosome maturation are key steps in the clearance of Mtb (Weiss 
and Schaible, 2015), we speculate that inhibiting PIKfyve would lead to 
an increase in bacterial burden. This increase in bacterial burden was 
observed in Mtb-infected BMMs when treated with MF4, a selective 
Pikfyve inhibitor, (Supplementary Fig. 5) and Dr. Maximiliano 
Gutierrez observed the same increase upon knocking down PIKfyve in 
macrophage cell lines and infecting with Mtb (personal 
communication). 
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 C2062 is targeting a pathway that can increase pro-
inflammatory mediators while reducing IL-10, without exacerbating 
immunopathology in the lung. Even though we do not know the exact 
target of C2062, we have identified and proven that these pathways 
are critical for the control of TB. Dr. Ruslana Bryk is carrying out 
experiments on the mechanism of action of C2062, and those studies 
will be reported elsewhere. 
  We observed that C2062 by itself reduced bacterial burden by 
0.5 log10 in lungs of Mtb-infected mice twice. However, in our 
combination experiment with C2062 and rif, C2062 had no effect on 
its own unlike the two previous experiments, but modestly augmented 
the robust impact of rif. We speculate that the key difference between 
the experiments may be attributed to delay in the start of treatment in 
the combination experiment, day 25 as opposed to day 14 in the 
previous experiments. We observed that IL-10 was high in myeloid 
cells isolated from lung draining lymph nodes in Mtb-infected mice on 
day 21, and IL-10 was below the limit of detection in myeloid cells in 
lung draining lymph nodes of Mtb-infected mice on day 42. This may 
have shrunken the window of opportunity for C2062 to act as HDT 
since one of the key features of C2062 is to lower IL-10 production. IL-
10 has been shown to block phagosome maturation in Mtb-infected 
human macrophages (O’Leary et al., 2011). Thus, lowering IL-10 early 
in the infection might lead to improved clearance of Mtb. We are 
planning to repeat the combination experiment as described in Fig. 23, 
starting the treatment of compounds on day 14 post infection. 
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 In summary, we have identified candidates for HDT of TB, and 
also identified pathways whose inhibition could be critical for control 
of Mtb. However, the mechanism of action of these small molecules 
remains yet to be elucidated. 
 
METHODS 
Macrophage culture, Mtb infection in mice, kinase selectivity 
assay and measurements of cytokines and RNI 
These protocols are described in detail in Chapter 2. 
 
Macrophage infection 
H37Rv strain was from R. North (Trudeau Institute). Macrophages 
were seeded in 48-well plates at a density of 2.0 × 10^5 cells per well 
with or without 10 ng/ml IFNγ (Roche) for 24 hrs. The macrophages 
were infected at an M.O.I of 0.1 of Mtb from early log phase cultures 
(O.D 0.6 – 0.8). 4 hr after infection, monolayers were washed twice 
with pre-warmed PBS to remove extracellular bacteria. Fresh complete 
medium was added to all wells. Next day, the media in wells was 
completely replaced with new media (10% LCM) with and without IFNγ 
(as primed before) and small molecules at desired concentrations. At 
day 1, 3 and 5 post-treatment of compounds, monolayers were lysed 
with 0.5% Triton X-100 by incubating at 37°C for 10 mins. Serial 
dilutions were plated on agar plates (Middlebrook 7H11, 10% OADC 
enrichment; Difco). CFUs were evaluated after 21 days at 37°C. All 
assays were done with three wells per condition in two independent 
experiments. 
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RNA isolation and real-time qPCR 
Total RNA isolation from BMM was performed using Qiagen RNAeasy 
Kit) and DNase digestion using Qiagen kit as per manufacturer’s 
protocol. cDNA was made using Quanta Bioscience qScript cDNA 
synthesis kit (#95049). PerfecTa qPCR FastMix, UNG from Quanta 
Biosciences was used as Mix (#95076). Real-time quantitative PCR was 
performed using validated TaqMan Gene Expression primer and 
probe sets (Life Technologies) according to the manufacturer’s 
instructions. Following primer and probe sets were used:  
Tnf (Mm00443258_m1), Nos2 (Mm00440502_m1), Il10 
(Mm01288386_m1) and Gapdh (Mm99999915_g1). qRT-PCR reactions 
were carried out using the ABI PRISM 7700 Sequence System (Applied 
Biosystems). mRNA expression was calculated using the 2−ΔCt method 
using GAPDH as the internal reference control. 
 
RNA-seq 
BMM from three C57BL/6J mice were treated with DMSO, C85, 
C2062 and C2753 (all at 10 µM) for 1 hr, 2 hr, and 6 hr, and RNA was 
isolated using Qiagen RNA-easy kit. Quality control of RNA and 
libraries was performed using the BioAnalyzer 2100. Pair-end 
sequencing with 40-50 million reads prepared and sequenced using 
Illumina Hi-Seq platform was performed at the Weill Cornell Genomics 
Core Facility. The RNA-seq data was analyzed by Weill Cornell 
Genomics Core Facility using DE-seq algorithm. Genes differentially 
expressed (~2fold) at FDR 10% and p<0.05 were clustered for further 
analysis. 
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Cytokine and nitrate/ nitrite measurements in lung homogenates 
and serum 
Lungs were homogenized in PBS containing Complete Mini, EDTA-free 
protease inhibitor (Roche Applied Science) and the debris-free 
supernatant was collected for cytokine measurement and stored at -80 
°C until further use. Secreted cytokines lung homogenates were 
measured by magnetic bead-based assays (Affymetrix) according to the 
manufacturers’ instructions. Data were acquired and analyzed using 
the Luminex automated system at Rockefeller University with the 
assistance of Dr. Juana Gonzalez. Nitrate/Nitrite Assay Kit by Cayman 
Biochemicals was used to measure nitrate/nitrite concentrations as 
per the kit protocol. 
 
Antibodies and Flow Cytometry 
Flow cytometric analyses of single cell suspension of cells from lung 
draining lymph nodes, lungs, and bronchoalveolar lavage was done on 
LSR-II (BD Immunocytometry Systems), and data analysis was 
performed using FlowJo software (Tree Star version 9.9). 
 
 
 
 
 
 
 
 
Antibody List Format Dilution Isotype Clone Company Catalog No.
iNOS (NOS Type 2) FITC 1/200 BD Pharmingen 610331
CD4 (L3T4) PerCP-Cy5.5 1/500 Rat IgG2a, κ RM4-5 Tonbo Bioscience 65-0042-U100
CD8a, Ly-2 PerCP-Cy5.5 1/500 Rat IgG2a, κ 53-6.7 Tonbo Bioscience 65-0081-U025
CD45R (B220) PerCP-Cy5.5 1/500 Rat IgG2a, κ RA3-6B2 eBioscience 45-0452-82
NK-1.1 PerCP-Cy5.5 1/250 IgG2a BioLegend 108728
CD11c (Integrin αX, p150/90)APC 1/500 Ar Ham IgG N418 eBioscience 17-0114-82
CD45( LCA, Ly-5 ) AlexaFluor 700 1/500 IgG2b, κ 30-F11 eBioscience 56-0451-82
Ly-6C APC-eFluor 780 1/1000 Rat IgG2c, κ HK1.4 eBioscience 47-5932-82
F4|80 Brilliant Violet 605 Rat IgG2a, k BM8 BioLegend 123133
CD11b PE-eFluor610 1/1500 Rat IgG2b, κ M1/70 eBioscience 61-0112-82
TNFα PE-Cy7 IgG1 MP6-XT22BD Pharmingen™ 557644
Ghost&Dye™&&& Violet 510 1/1000 Tonbo 13#0870#T100(
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Ingenuity Pathway Analysis (IPA) 
Ingenuity Knowledge Base (Ingenuity System, Redwood City, CA) was 
used to identify common pathways in the data set generated from 
RNA-seq at 6 hr time-point on macrophages treated with C85, C2062, 
and C2753. 
 
Statistics 
Results shown are mean values ± SEM unless otherwise stated. 
Student's unpaired two-tailed t-test was used for comparisons 
involving two groups. Differences between groups were considered 
significant when p ≤ 0.05. All statistical analyses were performed using 
GraphPad Prism 7.0 software (La Jolla, CA). 
 
Contributions 
R. Bryk conceived ideas as mentioned in the text. Tuo Zhang analyzed 
the RNA-seq data. X. Jiang administered the compounds in mice in all 
four experiments. J. Roberts performed the MIC assays. J. Roberts 
assisted with CFU assays for Mtb-infected macrophages and S. 
Mundhra analyzed and graphed the data. Femurs from IL-10-/- mice 
were a generous gift from Dr. Randy Longman (Weill Cornell Medicine). 
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 CONCLUSIONS 
 
 Increasing emergence of drug-resistant Mycobacterium 
tuberculosis (Mtb), the causative agent of tuberculosis (TB), led to 
interest in developing adjunctive therapies targeting host molecules to 
avoid pathogen resistance. An ideal candidate for host-directed 
therapy (HDT) would be a host enzyme whose temporary, partial 
inhibition is selectively detrimental for Mtb pathogenesis but not so for 
the host, and augments host immunity without exacerbating 
immunopathology. It was shown that mice deficient in protein kinase 
R (PKR) on 129S1/SvImJ background were partially protected from 
Mtb infection, in part due to reduction in interferon gamma (IFNγ) - 
induced macrophage expression of interleukin 10 (IL-10) (Wu et al., 
2012). The authors of this study concluded that the absence of PKR 
led to “super-activation of macrophages,” as indicated by an increase 
in the IFNγ–induced production of reactive nitrogen intermediates 
(RNI) and pro-inflammatory cytokine tumor necrosis factor alpha 
(TNFα) and decrease in anti-inflammatory cytokine IL-10 (Wu et al., 
2012).  
  Since PKR-deficiency led to improved control of TB, we 
collaborated with Celgene Global Health (CGH) to develop non-toxic 
small molecules targeting PKR that are bioavailable for HDT of TB in 
vivo. Among the small molecules we screened, we selected those which 
enhanced release of RNI and TNFα while reducing IL-10. For this 
purpose, we used IFNγ –primed bone marrow derived macrophages 
(BMM) from wild-type (WT) C57BL/6J mice. In a mouse model of Mtb 
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infection, one such small molecule - C2062 reduced Mtb-burden in 
lungs by 0.5 log10 without exacerbating immunopathology in lung. 
This decrease in bacterial burden in lungs correlated with increase in 
neutrophils and CD11b+ TNFa+ iNOS+ cells in lung draining lymph 
nodes and bronchoalveolar lavage fluid, and pro-inflammatory 
cytokine levels in lung homogenates. This suggested that these 
molecules are modulating important immune signaling pathways that 
lead to improved Mtb control in vivo. In combination with rifampicin 
(rif), a known antibiotic active against Mtb, C2062 reduced bacterial 
burden by 0.5 log10 in Mtb-infected BMMs compared to rif alone. 
Furthermore, C2062 modestly augmented the robust effects of rif in a 
mouse model of Mtb infection. 
  However, the small molecules – C2062  and C85 had similar 
effects on IFNγ – primed BMMs WT and PKR-deficient C57BL/6J mice 
excluding PKR as the its sole target. Furthermore, WT and PKR-
deficient mice with a shared C57BL/6J background, had similar Mtb 
burden in lungs and spleen, ruling out the relevance of PKR in TB.  
Even though we identified that the earlier phenotypes observed in the 
Wu study (Wu et al., 2012) were mouse strain-specific and PKR-
independent, nonetheless it led to the identification of novel PKR 
inhibitors with great selectivity.  
 We have identified that small molecule-mediated enhancement 
of macrophage activation can be used as agents for HDT, to help the 
immune system control TB in conjunction with anti-mycobacterials. 
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Future directions and perspectives: 
 This study demonstrates that PKR is not the ideal target for HDT 
of TB. The knowledge that PKR is not required for host control of TB in 
mice helps the scientific community and the pharmaceutical industry, 
to avoid investing further in discovery of PKR inhibitors in the context 
of TB treatment. In addition, the PKR inhibitors identified in our 
screen (chapter 2) may have value for pathological conditions other 
than TB. For instance, they may be used for other diseases such as 
insulin resistance, neurodegeneration and cancer where PKR 
inhibition has shown to be beneficial (Mouton-Liger et al., 2015; 
Nakamura et al., 2014; Pataer et al., 2009). 
 Moreover, this study highlights the importance and cautions the 
investigators of using strain-matched backgrounds in studies prior to 
making any scientific conclusions. The microbiome has been 
implicated in many disease settings (Cho and Blaser, 2012; Shreiner et 
al., 2015), however, the importance of co-housed littermate controls 
has just started to gain recognition. Herein, we used co-housed 
genetically-matched strains to account for the differences in 
microbiota. 
 In this study, we made the serendipitous discovery that 
macrophages from 129S1/SvImJ mice are more activated than 
macrophages of C57BL/6J mice upon IFNg treatment. This 
information could also be useful in urging the scientific community to 
be cautious while interpreting results in mouse models of various 
diseases where phenotypes are IFNg-dependent. In the earlier days, 
targeted mutagenesis in mice was mostly performed by using 
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embryonic stem cells from 129-derived mice, and C57BL/6J as 
recipient strains. It has been predicted though comparative genomics 
that nearly all 129-derived genetically modified congenic mice are 
affected by multiple inactivating passenger mutations which influence 
the phenotypic outcome, despite intensive backcrossing (Vanden 
Berghe et al., 2015). The authors of this study showed that there are 
indels and SNPs that result in aberrant or alternative amino acid 
sequences in 1,084 genes in the 129-strain genome. Hence, there is a 
highly underestimated issue of false-positive results using genetically 
modified lines. These confounding results could be one of the reasons 
leading to variable translatability of the results of mouse studies to 
humans.  
 Additionally, macrophages from 129S1/SvImJ mice, when 
treated with IFNg result in similar phenotypes, as what we would 
expect from knocking out of knocking down the target in macrophages 
from C57BL/6J mice treated with IFNg and our compound. Therefore, 
the phenotypes are manifested in activated 129S1/SvImJ 
macrophages without the compound, and the compound has no 
further effect. The latter macrophages could potentially be useful in 
identification of a candidate target. We could have potential targets in 
B6 background and look for a diminution of the function of that 
candidate target in 129S1/SvImJ genome to confirm the target.  
A caveat of our study is that mice on C57BL/6J background are 
not the best model of TB, since they do not form human-like 
granulomas. In addition, most mice strains seem to be unable to 
decrease bacterial burden and ultimately die of TB (Apt and Kramnik, 
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2009). Macaques are better compared to mice, as they can model 
granuloma structure and differential clinical outcomes of human 
infection and disease. However, they are also expensive to maintain 
and not suitable for preliminary studies. 
The RNA-seq data obtained on macrophages treated with C85 
and C2062 remains a largely unmined bed of useful information. The 
results of this screen lend itself well to candidate approaches for 
understanding macrophage activation. This is especially true for 
pathways hit in context of treatment with both candidate molecules – 
C85 and C2062.  
Loss of function screens may also be carried out for 
identification of the target(s) of the compound that gives the three 
phenotypes of increase in nitrite and TNFa production and IL-10 
reduction. However, this type of screen does have certain limitations – 
(1) the phenotypes could be a result of inhibition of multiple targets 
and hence a library of single-gene loss of function mutants may not 
contain any clones that would result in the phenotype, (2) loss of 
function screens can result in lethality if the candidate gene is 
essential for survival. 
Although the use of antibiotics is well established for the 
treatment of TB, due to the long duration of current TB therapy, it is 
expensive and difficult for patients to adhere to treatment. Hence, the 
need for an HDT agent is warranted. Preliminary experiments have 
suggested that C2062 in combination with rif results in marginally 
decreased CFU burden. We are currently starting a repeat experiment 
with a reduced dose of rif and earlier start of treatment of compounds 
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– day 14 instead of day 28 as performed previously (Chapter 3). If 
future studies can identify the physiologically relevant target of C2062, 
it will facilitate the development of more selective inhibitors against 
that target and lead to potential new therapeutic avenues for HDT 
against Mtb. Furthermore, small molecules enhancing macrophage 
activation could also find potential use in the context of other diseases 
where macrophages play a key role in clearance of pathogen such as 
Leishmania and Listeria (Bogdan and Röllinghoff, 1998; Pamer, 2004; 
Thi et al., 2012). 
Although more work is needed to elucidate how C2062 acts 
mechanistically, we have identified a direct correlation between the 
actions of C2062 (increase in percentage of neutrophils and iNOS+ 
TNFa+ myeloid cells) and reduction in bacterial burden. Hence, these 
phenotypes do have physiological relevance and do lead to improved 
TB control. This work may aid in the development of more therapeutic 
strategies to develop the small molecules targeting these pathways. My 
colleague, R. Bryk is carrying out research to understand mechanism 
of C2062 and those results will be reported elsewhere. 
It is not known why diabetes increases the risk of TB. It has 
been shown that inhibiting PKR improves glucose homeostasis in 
obese diabetic mice (Nakamura et al., 2014). Perhaps in a dual disease 
model of diabetes and TB, treatment with C2062, which enhances 
macrophage activation and inhibits PKR (IC50 = 0.88 µM as reported 
by R. Bryk), might prove to be beneficial.  
 The prime motivation for our work is the breadth and depth of 
human suffering caused by TB around the world. Of the other major 
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diseases, worldwide, many affect primarily older individuals (cancer, 
cardiovascular diseases) or young children (diarrheal diseases). TB, 
especially in the world of growing HIV prevalence and co-infection, 
affects primarily working-age adults. Thus, TB is devastating socio-
economically and pathologically. Poor communities, those most 
affected by the HIV and TB epidemics, are particularly vulnerable to 
losing members of their workforce. From a human perspective, the loss 
is much more difficult to calculate. TB is both the cause and a 
consequence of poverty. It is inextricably linked to those in under-
served and under-resourced communities of the world. Accordingly, 
there is an immediate and urgent need to reduce the cost and duration 
of TB treatment. Our efforts aimed at developing a novel adjunctive 
method to target TB necessarily fall within this global context. Here, 
we made a small attempt towards developing a potential new therapy 
against TB and understanding the biology behind it. Many promising 
potential host-directed therapeutics are already being explored in 
clinical trials (as described in Chapter 1). At the same time, we must 
also continue the development of antibiotics against Mtb, since drug 
resistance is a constant battle for all novel drugs. Efforts need to be 
made on all levels to translate our current understanding of TB in 
order to create effective treatments, preventions, and programs for its 
eradication. With the development of novel and effective adjunctive 
therapy, more effective vaccines and quicker-acting anti-
mycobacterials —the goal of TB eradication will be ever closer. 
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Supplementary Table 1. 
Data obtained by searching for ‘Ifngr1’ and ‘Ifngr2’ in mouse strain 
129S1SvImJ from 
http://www.sanger.ac.uk/sanger/Mouse_SnpViewer/rel-1505.  
The data-base uses mouse strain C57BL/6J GRCm38 assembly as a 
reference. All SNP/ indels and structural variant types were included 
in the search.  
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Supplementary Table 2. 
Using Ensemble’s Variant Predictor software, the following lists were 
generated with the biotypes mentioned. IMPACT: LOW = Assumed to 
be harmless. IMPACT: MODIFIER = Usually non-coding variants or 
variants affecting non-coding genes, where predictions are difficult or 
there is no evidence of impact. 
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Supplementary Table 2 (Contd.) 
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Supplementary Table 2 (Contd.) 
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Supplementary Fig. 1. Common genes upregulated by C85 and 
C2062 at 1 hr (A) and 2 hr (B) post treatment. 
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Supplementary Fig. 2. Common genes downregulated by C85 and 
C2062 at 1 hr (A) and 2 hr (B) post treatment.
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Supplementary Fig 3. Comparison analysis between 85, 2062 and 
2753 at 6h showing some of the top significant upregulated 
pathways.
 
 
 
121 
NT
-1
Ve
hic
le-
1
20
62
-1
NT
-2
Ve
hic
le-
2
20
62
-2
0
10
20
30
40
Nitrite-production - MHS cell line
N
itr
ite
 (µ
M
)
No IFNγ - 24h
+ IFNg (10 ng/ml) - 24h
No IFNγ - 48h
+ IFNg (10 ng/ml) - 48h
NT
-1
Ve
hic
le-
1
20
62
-1
NT
-2
Ve
hic
le-
2
20
62
-2
0
10
20
30
40
Nitrite-production - MHS cell line
N
itr
ite
 (µ
M
)
No IFNγ - 24h
+ IFNg (10 ng/ml) - 24h
No IFNγ - 48h
+ IFNg (10 ng/ml) - 48h
NT##########Vehicle########2062
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Fig. 4. C2062 increases nitrite levels in a murine 
alveolar macrophage cell line. 
 
We next wanted to investigate if the phenotypes we observed were 
applicable to other macrophages or not. My colleague, Ruslana Bryk, 
observed the same phenotypes in RAW264 murine macrophage cell 
line (data not shown). I tested C2062 on MHS, a murine alveolar 
macrophage cell line and observed that it did elevate nitrite levels in 
that cell line as well. 
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Supplementary Fig. 5. Similar Mtb burden in vehicle and MF4 
treated macrophages.  
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